Lym-1 and lym-2 targeted car cell immunotherapy

ABSTRACT

CAR cells targeting and antibodies human HLA-DR are described as a new method of cancer treatment. It is proposed that HLA-DR CAR cells are safe and effective in patients and can be used to treat human tumors expressing the HLA-DR.

CROSS-REFERENCE TO RELATED APPLICATION

This application claims priority under 35 U.S.C. § 119(e) to U.S.Provisional Application No. 62/171,004, filed Jun. 4, 2015, the contentof which is hereby incorporated by reference in its entirety.

SEQUENCE LISTING

The instant application contains a Sequence Listing which has beensubmitted electronically in ASCII format and is hereby incorporated byreference in its entirety. Said ASCII copy, created on Jun. 1, 2016, isnamed 064189-7201_SL.txt and is 51,805 bytes in size.

BACKGROUND

The present disclosure relates generally to the field of humanimmunology, specifically cancer immunotherapy.

The following discussion of the background is merely provided to aid thereader in the understanding the disclosure and is not admitted todescribe or constitute prior art to the present disclosure.

Lym-1 and Lym-2 are directed against MHC class II HLA-DR molecules whichare primarily expressed on the surface of human B cells, dendriticcells, and B-cell derived lymphomas and leukemias.

SUMMARY

Provided are methods and compositions relating to new cancerimmunotherapeutic chimeric antigen receptors (CARs). Aspects of thedisclosure relate to a chimeric antigen receptor (CAR) comprising, oralternatively consisting essentially of, or yet further consisting of:(a) an antigen binding domain of a Lym-1 and/or Lym-2 antibody; (b) ahinge domain; (c) a transmembrane domain; and (d) an intracellulardomain. Further aspects of the disclosure relate to a chimeric antigenreceptor (CAR) comprising, or alternatively consisting essentially of,or yet further consisting of: (a) an antigen binding domain of a Lym-1and/or Lym-2 antibody; (b) a CD8 α hinge domain; (c) a CD8 αtransmembrane domain; (d) a CD28 costimulatory signaling region and/or a4-1BB costimulatory signaling region; and (e) a CD3 zeta signalingdomain.

Aspects of the disclosure relate to Lym-1 and Lym-2 antibodies.

Some aspects of the disclosure relate to a chimeric antigen receptor(CAR) comprising an antigen binding domain specific to human HLA-DRantigens—for example, the antigen binding domain of Lym-1 and Lym-2antibodies.

Further aspects of the disclosure relate to an isolated nucleic acidsequence encoding a Lym1 or Lym-2 CARs and vectors comprising theisolated nucleic acid sequences.

Other aspects of the disclosure relate to an isolated cell comprising aLym-1 or Lym-2 directed CAR and methods of producing such cells. Stillother method aspects of the disclosure relate to methods for inhibitingthe growth of a tumor and treating a cancer patient comprising, oralternatively consisting essentially of, or yet further consisting of,administering an effective amount of the isolated cell to a tissue orsubject in need of such.

Further method aspects of the disclosure relate to methods fordetermining if a patient is likely or unlikely to respond to Lym-1 CARor Lym-2 CAR therapy through use of one or more of the Lym-1 or Lym-2antibodies and/or the Lym-1 CAR or Lym-2 CAR cells.

Additional aspects of the disclosure relate to compositions comprising acarrier and one or more of the products described in the embodimentsdisclosed herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1F show flow cytometric analysis of (FIG. 1A) negative control;(FIG. 1B) Lym-1; (FIG. 1C) Lym-1 and B1; (FIG. 1D) B1 only; (FIG. 1E)Lym-2; and (FIG. 1F) Lym-2 and B1 staining reactivity with normalperipheral blood lymphocytes of patients. Both Lym-1 and Lym-2 havedifferent profiles of binding to normal human peripheral B cells.

FIGS. 2A-2B show Lym-1 and Lym-2 staining of normal human tonsildemonstrating membrane positivity in B-cell germinal centers.Differences in staining patterns are evident between Lym-1 (FIG. 2A) andLym-2 (FIG. 2B). Only scattered interfollicular dendritic cells arepositive for both antibodies in the T-cell zones (IHC, frozen sections,×325).

FIGS. 3A and 3B show immunoperoxidase staining of Lym-1 and Lym-2monoclonal antibodies with an intermediate grade malignant B-celllymphoma. Immunoperoxidase staining of Lym-1 (FIG. 3A) and Lym-2 (FIG.3B) monoclonal antibodies with an intermediate grade malignant B-celllymphoma (frozen sections, ×720). Note prominent membrane stainingpattern of majority of cells in the section.

FIGS. 4A-4C show binding profiles and Scatchard Plots of (FIG. 4A)Binding profiles of Lym-1 monoclonal antibodies to Raji cells and Lym-2monoclonal antibodies to ARH-77 cells; (FIG. 4B) Scatchard plot analysisof Lym-1 monoclonal antibodies with Raji cells; (FIG. 4C) Scatchard plotanalysis of Lym-2 monoclonal antibodies with ARH-77 cells.

FIGS. 5A and 5B show immunoprecipitation of ³⁵S-methionine and¹⁴C-leucine-labeled Raji proteins by Lym-1 (FIG. 5A) and SC-2anti-HLA-DR antibody (FIG. 5B).

FIGS. 6A and 6B show a construction schematic of (FIG. 6A) Lym-1 and(FIG. 6B) Lym-2 CAR T-cells for immunotherapy. FIGS. 6A and 6B discloseSEQ ID NO: 51.

FIG. 7 depicts a schematic a non-limiting exemplary Lym-1 gene-transfervector and transgene. The backbone of the gene transfer vector is anHIV-based, bicistronic lentiviral vector, pLVX-IRES-ZsGreen containingHIV-1 5′ and 3′ long terminal repeats (LTRs), packaging signal (Ψ), EF1αpromoter, internal ribosome entry site (IRES), ZsGreen, a greenfluorescent protein, woodchuck hepatitis virus post-transcriptionalregulatory element (WPRE), and simian virus 40 origin (SV40).Constitutive expression of the transgene comprising of αCD8 leadersequence, a scFV specific to Lym-1, a CD8 hinge and transmembrane regionand 4-1BB and CD3ζ signaling domain, is insured by the presence of theEF-1α promoter. Expression of the detection protein, ZsGreen is carriedout by the IRES region. Integration of the vector can be assayed by thepresence of ZsGreen in the cells, via fluorescent microscopy.

FIG. 8 shows expression of Lym-1 CAR on primary human T-cells. T-cellswere transduced with the Lym-1 CAR and stained with Biotein-Protein L,followed by Streptavidin-PE. Cells were analyzed by flow cytometry.

FIG. 9 shows cytotoxicity of the Lym-1-CAR T-cells. Cytotoxicity of theLym-1 CAR expressing T-cells was determined using an LDH cytotoxicitykit as described in the Methods. Prior to the assay, T-cells wereactivated using αCD3/CD8 beads (Stem Cell Technologies, 30 ul to 2 ml ofmedia). The activated T-cells were transduced with Lym-1 CAR lentiviralparticles, following which the T cells were activated using the αCD3/CD8beads. Un-transduced, activated T-cells were used as a control. 15,000Raji cells were plated per well. Lym-1 CAR transduced T cells were addedin ratios of 20:1, 10:1, 5:1 and 1:1 to the wells. Each data pointrepresents the average of triplicate measurements.

FIG. 10 depicts a schematic a non-limiting exemplary Lym-2 gene-transfervector and transgene. The backbone of the gene transfer vector is anHIV-based, bicistronic lentiviral vector, pLVX-IRES-ZsGreen containingHIV-1 5′ and 3′ long terminal repeats (LTRs), packaging signal (Ψ), EF1αpromoter, internal ribosome entry site (IRES), ZsGreen, a greenfluorescent protein, woodchuck hepatitis virus post-transcriptionalregulatory element (WPRE), and simian virus 40 origin (SV40).Constitutive expression of the transgene comprising of a CD8 leadersequence, an scFV specific to Lym-2, a CD8 hinge and transmembraneregion and CD28, 4-1BB and CD3ζ signaling domain, is insured by thepresence of the EF-1α promoter. Expression of the detection protein,ZsGreen is carried out by the IRES region. Integration of the vector canbe assayed by the presence of ZsGreen in the cells, via fluorescentmicroscopy.

FIG. 11 shows expression of Lym-2 CAR on primary human T-cells. T-cellswere transduced with the Lym-2 CAR and stained with Biotein-Protein L,followed by Streptavidin-PE. Cells were analyzed by flow cytometry.

FIG. 12 shows cytotoxicity of the Lym-2-CAR T-cells. Cytotoxicity of theLym-2 CAR expressing T-cells was determined using an LDH cytotoxicitykit as described in the Methods. Prior to the assay, T-cells wereactivated using αCD3/CD8 beads (Stem Cell Technologies, 30 ul to 2 ml ofmedia). The activated T-cells were transduced with Lym-2 CAR lentiviralparticles, following which the T cells were activated using the αCD3/CD8beads. Un-transduced, activated T-cells were used as a control. 15,000Raji cells were plated per well. Lym-2 CAR transduced T cells were addedin ratios of 20:1, 10:1, 5:1 and 1:1 to the wells. Each data pointrepresents the average of triplicate measurements.

FIG. 13 demonstrates that Lym-1, Lym-2, and CD19 CAR T-cells are highlycytotoxic to human lymphoma Raji cells. Raji Burkitt's lymphoma cellsare positive for both HLA-Dr targeted by Lym-1 and Lym-2 and also CD19which acted as a positive control for CD19 CAR T-cells. Negativecontrols consisted of CD3+ T cells and Zsgreen cells.

FIG. 14 demonstrates that Lym-1, Lym-2, but not CD19 CAR are highlycytolytic against HLA-Dr positive but CD19 negative TLBR-2 human Tlymphoma cells in vitro. TLBR-2 human T-lymphoma cells derived from abreast implant associated lymphoma is positive for HLA-Dr but not CD19(Lechner et al. (2012) Clin. Cancer Res. 18 (17):4549-4559). Theseresults demonstrate the specificity of the Lym-1 and Lym-2 CAR T-cellsand their potency in killing HLA-Dr positive tumors. The percentage ofLym-1 CAR-T and CD19 CAR-T positive cells were adjusted to 50% usingregular un-transduced primary T cells. The percentage of Lym-2 CAR-Tcells was 24%.

FIG. 15 shows the results of FACs analysis of transfected NK cells.

DETAILED DESCRIPTION

It is to be understood that the present disclosure is not limited toparticular aspects described, as such may, of course, vary. It is alsoto be understood that the terminology used herein is for the purpose ofdescribing particular aspects only, and is not intended to be limiting,since the scope of the present disclosure will be limited only by theappended claims.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meanings as commonly understood by one of ordinary skillin the art to which this technology belongs. Although any methods andmaterials similar or equivalent to those described herein can be used inthe practice or testing of the present technology, the preferredmethods, devices and materials are now described. All technical andpatent publications cited herein are incorporated herein by reference intheir entirety. Nothing herein is to be construed as an admission thatthe present technology is not entitled to antedate such disclosure byvirtue of prior invention.

The practice of the present technology will employ, unless otherwiseindicated, conventional techniques of tissue culture, immunology,molecular biology, microbiology, cell biology, and recombinant DNA,which are within the skill of the art. See, e.g., Sambrook and Russelleds. (2001) Molecular Cloning: A Laboratory Manual, 3rd edition; theseries Ausubel et al. eds. (2007) Current Protocols in MolecularBiology; the series Methods in Enzymology (Academic Press, Inc., N.Y.);MacPherson et al. (1991) PCR 1: A Practical Approach (IRL Press atOxford University Press); MacPherson et al. (1995) PCR 2: A PracticalApproach; Harlow and Lane eds. (1999) Antibodies, A Laboratory Manual;Freshney (2005) Culture of Animal Cells: A Manual of Basic Technique,5th edition; Gait ed. (1984) Oligonucleotide Synthesis; U.S. Pat. No.4,683,195; Hames and Higgins eds. (1984) Nucleic Acid Hybridization;Anderson (1999) Nucleic Acid Hybridization; Hames and Higgins eds.(1984) Transcription and Translation; Immobilized Cells and Enzymes (IRLPress (1986)); Perbal (1984) A Practical Guide to Molecular Cloning;Miller and Calos eds. (1987) Gene Transfer Vectors for Mammalian Cells(Cold Spring Harbor Laboratory); Makrides ed. (2003) Gene Transfer andExpression in Mammalian Cells; Mayer and Walker eds. (1987)Immunochemical Methods in Cell and Molecular Biology (Academic Press,London); and Herzenberg et al. eds (1996) Weir's Handbook ofExperimental Immunology.

All numerical designations, e.g., pH, temperature, time, concentration,and molecular weight, including ranges, are approximations which arevaried (+) or (−) by increments of 1.0 or 0.1, as appropriate, oralternatively by a variation of +/−15%, or alternatively 10%, oralternatively 5%, or alternatively 2%. It is to be understood, althoughnot always explicitly stated, that all numerical designations arepreceded by the term “about”. It also is to be understood, although notalways explicitly stated, that the reagents described herein are merelyexemplary and that equivalents of such are known in the art.

It is to be inferred without explicit recitation and unless otherwiseintended, that when the present technology relates to a polypeptide,protein, polynucleotide or antibody, an equivalent or a biologicallyequivalent of such is intended within the scope of the presenttechnology.

Definitions

As used in the specification and claims, the singular form “a”, “an”,and “the” include plural references unless the context clearly dictatesotherwise. For example, the term “a cell” includes a plurality of cells,including mixtures thereof.

As used herein, the term “animal” refers to living multi-cellularvertebrate organisms, a category that includes, for example, mammals andbirds. The term “mammal” includes both human and non-human mammals.

The terms “subject,” “host,” “individual,” and “patient” are as usedinterchangeably herein to refer to human and veterinary subjects, forexample, humans, animals, non-human primates, dogs, cats, sheep, mice,horses, and cows. In some embodiments, the subject is a human.

As used herein, the term “antibody” collectively refers toimmunoglobulins or immunoglobulin-like molecules including by way ofexample and without limitation, IgA, IgD, IgE, IgG and IgM, combinationsthereof, and similar molecules produced during an immune response in anyvertebrate, for example, in mammals such as humans, goats, rabbits andmice, as well as non-mammalian species, such as shark immunoglobulins.Unless specifically noted otherwise, the term “antibody” includes intactimmunoglobulins and “antibody fragments” or “antigen binding fragments”that specifically bind to a molecule of interest (or a group of highlysimilar molecules of interest) to the substantial exclusion of bindingto other molecules (for example, antibodies and antibody fragments thathave a binding constant for the molecule of interest that is at least10³ M⁻¹ greater, at least 10⁴M⁻¹ greater or at least 10⁵ M⁻¹ greaterthan a binding constant for other molecules in a biological sample). Theterm “antibody” also includes genetically engineered forms such aschimeric antibodies (for example, humanized murine antibodies),heteroconjugate antibodies (such as, bispecific antibodies). See also,Pierce Catalog and Handbook (1994-1995) (Pierce Chemical Co., Rockford,Ill.); Kuby, J. (1997) Immunology, 3^(rd) Ed., W.H. Freeman & Co., NewYork. An “antigen binding fragment” of an antibody is a portion of anantibody that retains the ability to specifically bind to the targetantigen of the antibody.

As used herein, the term “monoclonal antibody” refers to an antibodyproduced by a single clone of B-lymphocytes or by a cell into which thelight and heavy chain genes of a single antibody have been transfected.Monoclonal antibodies are produced by methods known to those of skill inthe art, for instance by making hybrid antibody-forming cells from afusion of myeloma cells with immune spleen cells. Monoclonal antibodiesinclude humanized monoclonal antibodies and human antibodies.

In terms of antibody structure, an immunoglobulin has heavy (H) chainsand light (L) chains interconnected by disulfide bonds. There are twotypes of light chain, lambda (λ) and kappa (κ). There are five mainheavy chain classes (or isotypes) which determine the functionalactivity of an antibody molecule: IgM, IgD, IgG, IgA and IgE. Each heavyand light chain contains a constant region and a variable region, (theregions are also known as “domains”). In combination, the heavy and thelight chain variable regions specifically bind the antigen. Light andheavy chain variable regions contain a “framework” region interrupted bythree hypervariable regions, also called “complementarity-determiningregions” or “CDRs”. The extent of the framework region and CDRs havebeen defined (see, Kabat et al., Sequences of Proteins of ImmunologicalInterest, U.S. Department of Health and Human Services, 1991, which ishereby incorporated by reference). The Kabat database is now maintainedonline. The sequences of the framework regions of different light orheavy chains are relatively conserved within a species. The frameworkregion of an antibody, that is the combined framework regions of theconstituent light and heavy chains, largely adopts a β-sheetconformation and the CDRs form loops which connect, and in some casesform part of, the β-sheet structure. Thus, framework regions act to forma scaffold that provides for positioning the CDRs in correct orientationby inter-chain, non-covalent interactions.

The CDRs are primarily responsible for binding to an epitope of anantigen. The CDRs of each chain are typically referred to as CDR1, CDR2,and CDR3, numbered sequentially starting from the N-terminus, and arealso typically identified by the chain in which the particular CDR islocated (heavy chain regions labeled CDHR and light chain regionslabeled CDLR). Thus, a CDHR3 is the CDR3 from the variable domain of theheavy chain of the antibody in which it is found, whereas a CDLR1 is theCDR1 from the variable domain of the light chain of the antibody inwhich it is found. A TNT antibody will have a specific V_(H) region andthe V_(L) region sequence unique to the TNT relevant antigen, and thusspecific CDR sequences. Antibodies with different specificities (i.e.,different combining sites for different antigens) have different CDRs.Although it is the CDRs that vary from antibody to antibody, only alimited number of amino acid positions within the CDRs are directlyinvolved in antigen binding. These positions within the CDRs are calledspecificity determining residues (SDRs).

As used herein, the term “antigen” refers to a compound, composition, orsubstance that may be specifically bound by the products of specifichumoral or cellular immunity, such as an antibody molecule or T-cellreceptor. Antigens can be any type of molecule including, for example,haptens, simple intermediary metabolites, sugars (e.g.,oligosaccharides), lipids, and hormones as well as macromolecules suchas complex carbohydrates (e.g., polysaccharides), phospholipids, andproteins. Common categories of antigens include, but are not limited to,viral antigens, bacterial antigens, fungal antigens, protozoa and otherparasitic antigens, tumor antigens, antigens involved in autoimmunedisease, allergy and graft rejection, toxins, and other miscellaneousantigens.

As used herein, the term “antigen binding domain” refers to any proteinor polypeptide domain that can specifically bind to an antigen target.

The term “chimeric antigen receptor” (CAR), as used herein, refers to afused protein comprising an extracellular domain capable of binding toan antigen, a transmembrane domain derived from a polypeptide differentfrom a polypeptide from which the extracellular domain is derived, andat least one intracellular domain. The “chimeric antigen receptor (CAR)”is sometimes called a “chimeric receptor”, a “T-body”, or a “chimericimmune receptor (CIR).” The “extracellular domain capable of binding toan antigen” means any oligopeptide or polypeptide that can bind to acertain antigen. The “intracellular domain” means any oligopeptide orpolypeptide known to function as a domain that transmits a signal tocause activation or inhibition of a biological process in a cell. Incertain embodiments, the intracellular domain may comprise,alternatively consist essentially of, or yet further comprise one ormore costimulatory signaling domains in addition to the primarysignaling domain. The “transmembrane domain” means any oligopeptide orpolypeptide known to span the cell membrane and that can function tolink the extracellular and signaling domains. A chimeric antigenreceptor may optionally comprise a “hinge domain” which serves as alinker between the extracellular and transmembrane domains. Non limitingexamples of such domains are provided herein, e.g.:

Hinge domain: IgG1 heavy chain hinge sequence, SEQ ID NO: 42:

CTCGAGCCCAAATCTTGTGACAAAACTCACACATGCCCACCGTGCCCGTransmembrane domain: CD28 transmembrane region SEQ ID NO: 43:

TTTTGGGTGCTGGTGGTGGTTGGTGGAGTCCTGGCTTGCTATAGCTTGCTAGTAACAGTGGCCTTTATTATTTTCTGGGTGIntracellular domain: 4-1BB co-stimulatory signaling region, SEQ ID NO:44:

AAACGGGGCAGAAAGAAACTCCTGTATATATTCAAACAACCATTTATGAGACCAGTACAAACTACTCAAGAGGAAGATGGCTGTAGCTGCCGATTTCCAGAAGAAGAAGAAGGAGGATGTGAACTGIntracellular domain: CD28 co-stimulatory signaling region, SEQ ID NO:45:

AGGAGTAAGAGGAGCAGGCTCCTGCACAGTGACTACATGAACATGACTCCCCGCCGCCCCGGGCCCACCCGCAAGCATTACCAGCCCTATGCCCCACCACGCGACTTCGCAGCCTATCGCTCCIntracellular domain: CD3 zeta signaling region, SEQ ID NO: 46:

AGAGTGAAGTTCAGCAGGAGCGCAGACGCCCCCGCGTACCAGCAGGGCCAGAACCAGCTCTATAACGAGCTCAATCTAGGACGAAGAGAGGAGTACGATGTTTTGGACAAGAGACGTGGCCGGGACCCTGAGATGGGGGGAAAGCCGAGAAGGAAGAACCCTCAGGAAGGCCTGTACAATGAACTGCAGAAAGATAAGATGGCGGAGGCCTACAGTGAGATTGGGATGAAAGGCGAGCGCCGGAGGGGCAAGGGGCACGATGGCCTTTACCAGGGTCTCAGTACAGCCACCAAGGACACCTACGACGCCCTTCACATGCAGGCCCTGCCCCCTCGCTAA

As used herein, the term “HLA-DR” (refers to an MHC class II cellsurface receptor associated with this name and any other molecules thathave analogous biological function that share at least 80% amino acidsequence identity, preferably 90% sequence identity, or alternatively atleast 95% sequence identity with any HLA-DR variant, including but notlimited to any one of its several variants, including but not limited toHLA-DR serotypes DR1 to DR 75 comprising a combination of HLA-DRA andHLA-DRB haplotypes. Examples of the HLA-DR sequences are known in theart and non-limited examples of such are disclosed in Rose, L. M. et al.(1996) Cancer Immunol. Immunother. 43:26-30:

HLA-DRB1*1001 [DR10] SEQ ID NO: 30GDTRPRFLEEVKFECHFFNGTERVRLLERRVHNQEEYARYDSDVGEYRAVTELGRPDAEYWNSQKDLLERRRAAVDTYCRHNYGVGESFTVQRRVQPKVTVYPSKTQPLQHHNLLVCSVNGFYPGSIEVRWFRNGQEEKTGVVSTGLIQNGDWTFQTLVMLETVPQSGEVYTCQVEHPSVMSPLTVEWRARSESAQSKMLSGVGGFVLGLLFLGAGLFIYFRNQKGHSGLPPTGFLS; HLA-DRB3*0201 D[R52]SEQ ID NO: 31 GDTRPRFLELLKSECHFFNGTERVRFLERHFHNQEEYARFDSDVGEYRAVFELGRPDAEYWNSQKDLLEQKRGQVDNYCRHNYGVVESFTVQRRVHPQVTVYPAKTQPLQHHNLLVCSVSGFYPGSIEVRWFRNGQEEKAGVVSTGLIQNGDWTFQTLVMLETFPRSGEVYTCQVEHPSVTSPLTVEWSARSESAQSKMLSGVGGFVLGLLFLGAGLFIYFRNQKGHSGLQPTGFLS; HLA-DRB1*0301 [DR17 (3)]SEQ ID NO: 32 GDTRPRFLEYSTSECHFFNGTERVRYLDRYFHNQEENVRFDSDVGEFRAVTELGRPDAEYWNSQKDLLEQKRGRVDNYCRHNYGVVESFTVQRRVHPKVTVYPSKTQPLQHHNLLVCSVSGFYPGSIEVRWFRNGQEEKTGVVSTGLIQNGDWTFQTLVMLETVPRSGEVYTCQVEHPSVTSPLTVEWRARSESAQSKMLSGVGGFVLGLLFLGAGLFIYFRNQKGHSGLQPRGFLS,as well as equivalents of each thereof.

Rose et al. also discloses an exemplary epitope to which an HLA-DRspecific antibody may bind and therefore can serve as an immunogen forthe generation of additional antibodies, monoclonal antibodies andantigen binding fragments of each thereof. The sequences associated witheach of the listed reference(s) and GenBank Accession Numbers thatcorrespond to the name HLA-DR or its equivalents including but notlimited to the specified HLA-DR subtypes are herein incorporated byreference as additional non-limiting examples.

A “composition” typically intends a combination of the active agent,e.g., a CAR T cell or a CAR NK cell, an antibody, a compound, and anaturally-occurring or non-naturally-occurring carrier, inert (forexample, a detectable agent or label) or active, such as an adjuvant,diluent, binder, stabilizer, buffers, salts, lipophilic solvents,preservative, adjuvant or the like and include pharmaceuticallyacceptable carriers. Carriers also include pharmaceutical excipients andadditives proteins, peptides, amino acids, lipids, and carbohydrates(e.g., sugars, including monosaccharides, di-, tri,tetra-oligosaccharides, and oligosaccharides; derivatized sugars such asalditols, aldonic acids, esterified sugars and the like; andpolysaccharides or sugar polymers), which can be present singly or incombination, comprising alone or in combination 1-99.99% by weight orvolume. Exemplary protein excipients include serum albumin such as humanserum albumin (HSA), recombinant human albumin (rHA), gelatin, casein,and the like. Representative amino acid/antibody components, which canalso function in a buffering capacity, include alanine, arginine,glycine, arginine, betaine, histidine, glutamic acid, aspartic acid,cysteine, lysine, leucine, isoleucine, valine, methionine,phenylalanine, aspartame, and the like. Carbohydrate excipients are alsointended within the scope of this technology, examples of which includebut are not limited to monosaccharides such as fructose, maltose,galactose, glucose, D-mannose, sorbose, and the like; disaccharides,such as lactose, sucrose, trehalose, cellobiose, and the like;polysaccharides, such as raffinose, melezitose, maltodextrins, dextrans,starches, and the like; and alditols, such as mannitol, xylitol,maltitol, lactitol, xylitol sorbitol (glucitol) and myoinositol.

The term “consensus sequence” as used herein refers to an amino acid ornucleic acid sequence that is determined by aligning a series ofmultiple sequences and that defines an idealized sequence thatrepresents the predominant choice of amino acid or base at eachcorresponding position of the multiple sequences. Depending on thesequences of the series of multiple sequences, the consensus sequencefor the series can differ from each of the sequences by zero, one, afew, or more substitutions. Also, depending on the sequences of theseries of multiple sequences, more than one consensus sequence may bedetermined for the series. The generation of consensus sequences hasbeen subjected to intensive mathematical analysis. Various softwareprograms can be used to determine a consensus sequence.

As used herein, the term “CD8 α hinge domain” refers to a specificprotein fragment associated with this name and any other molecules thathave analogous biological function that share at least 70%, oralternatively at least 80% amino acid sequence identity, oralternatively at least 90% sequence identity, or alternatively at least95% sequence identity with the CD8 α hinge domain sequence as shownherein. The example sequences of CD8 α hinge domain for human, mouse,and other species are provided in Pinto, R. D. et al. (2006) Vet.Immunol. Immunopathol. 110:169-177. The sequences associated with theCD8 α hinge domain are provided in Pinto, R. D. et al. (2006) Vet.Immunol. Immunopathol. 110:169-177. Non-limiting examples of suchinclude:

Human CD8 alpha hinge domain (SEQ ID NO: 33);PAKPTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYMouse CD8 alpha hinge domain (SEQ ID NO: 34);KVNSTTTKPVLRTPSPVHPTGTSQPQRPEDCRPRGSVKGTGLDFACDIYCat CD8 alpha hinge domain (SEQ ID NO: 35);PVKPTTTPAPRPPTQAPITTSQRVSLRPGTCQPSAGSTVEASGLDLSCDIY, and equivalents ofeach thereof.

As used herein, the term “CD8 α transmembrane domain” refers to aspecific protein fragment associated with this name and any othermolecules that have analogous biological function that share at least70%, or alternatively at least 80% amino acid sequence identity, oralternatively at least 90% sequence identity, or alternatively at least95% sequence identity with the CD8 α transmembrane domain sequence asshown herein. The fragment sequences associated with the amino acidpositions 183 to 203 of the human T-cell surface glycoprotein CD8 alphachain (NCBI Reference Sequence: NP_001759.3), or the amino acidpositions 197 to 217 of the mouse T-cell surface glycoprotein CD8 alphachain (NCBI Reference Sequence: NP_001074579.1), and the amino acidpositions 190 to 210 of the rat T-cell surface glycoprotein CD8 alphachain (NCBI Reference Sequence: NP_113726.1) provide additional examplesequences of the CD8 α transmembrane domain. The sequences associatedwith each of the listed NCBI are provided as follows:

Human CD8 alpha transmembrane domain, (SEQ ID NO: 36):IYIWAPLAGTCGVLLLSLVIT;Mouse CD8 alpha transmembrane domain, (SEQ ID NO: 37):IWAPLAGICVALLLSLIITLI;Rat CD8 alpha transmembrane domain, (SEQ ID NO: 38):IWAPLAGICAVLLLSLVITLI, and equivalents of each thereof.

As used herein, the term “4-1BB costimulatory signaling region” refersto a specific protein fragment associated with this name and any othermolecules that have analogous biological function that share at least70%, or alternatively at least 80% amino acid sequence identity, oralternatively 90% sequence identity, or alternatively at least 95%sequence identity with the 4-1BB costimulatory signaling region sequenceas shown herein. The example sequences of the 4-1BB costimulatorysignaling region are provided in U.S. Patent Application Publication No.2013/0266551 A1 (filed as U.S. application Ser. No. 13/826,258). Thesequence of the 4-1BB costimulatory signaling region associateddisclosed in the U.S. application Ser. No. 13/826,258 is disclosed asfollows:

The 4-1BB costimulatory signaling region (SEQ ID NO: 39):KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL, and equivalents of eachthereof.

As used herein, the term “CD28 costimulatory signaling region” refers toa specific protein fragment associated with this name and any othermolecules that have analogous biological function that share at least70%, or alternatively at least 80% amino acid sequence identity, oralternatively 90% sequence identity, or alternatively at least 95%sequence identity with the CD28 costimulatory signaling region sequenceshown herein. The CD28 costimulatory region comprises an transmembranedomain and an intracellular domain. The example sequences CD28costimulatory signaling domain are provided in U.S. Pat. No. 5,686,281;Geiger, T. L. et al. (2001) Blood 98:2364-2371; Hombach, A. et al.(2001) J Immunol. 167:6123-6131; Maher, J. et al. (2002) Nat Biotechnol.20:70-75; Haynes, N. M. et al. (2002) J Immunol. 169:5780-5786; Haynes,N. M. et al. (2002) Blood 100:3155-3163. Non-limiting examples includeresidues 114-220 of the below CD28 Sequence, (SEQ ID NO: 40): MLRLLLALNLFPSIQVTGNK ILVKQSPMLV AYDNAVNLSC KYSYNLFSRE FRASLHKGLDSAVEVCVVYGNYSQQLQVYS KTGFNCDGKL GNESVTFYLQ NLYVNQTDIY FCKIEVMYPPPYLDNEKSNGTIIHVKGKHL CPSPLFPGPS KPFWVLVVVG GVLACYSLLVTVAFIIFWVR SKRSRLLHSDYMNMTPRRPG PTRKHYQPYA PPRDFAAYRS, and equivalents thereof.

As used herein, the term “ICOS costimulatory signaling region” refers toa specific protein fragment associated with this name and any othermolecules that have analogous biological function that share at least70%, or alternatively at least 80% amino acid sequence identity,preferably 90% sequence identity, more preferably at least 95% sequenceidentity with the ICOS costimulatory signaling region sequence as shownherein. Non-limiting example sequences of the ICOS costimulatorysignaling region are provided in U.S. Publication 2015/0017141A1 theexemplary polynucleotide sequence provided below.

ICOS costimulatory signaling region, SEQ ID NO: 47:ACAAAAAAGA AGTATTCATC CAGTGTGCAC GACCCTAACGGTGAATACAT GTTCATGAGA GCAGTGAACA CAGCCAAAAA ATCCAGACTC ACAGATGTGA CCCTA

As used herein, the term “OX40 costimulatory signaling region” refers toa specific protein fragment associated with this name and any othermolecules that have analogous biological function that share at least70%, or alternatively at least 80% amino acid sequence identity, oralternatively 90% sequence identity, or alternatively at least 95%sequence identity with the OX40 costimulatory signaling region sequenceas shown herein. Non-limiting example sequences of the OX40costimulatory signaling region are disclosed in U.S. Publication2012/20148552A1, and include the exemplary sequence provided below.

0X40 costimulatory signaling region, SEQ ID NO: 48:AGGGACCAG AGGCTGCCCC CCGATGCCCA CAAGCCCCCTGGGGGAGGCA GTTTCCGGAC CCCCATCCAA GAGGAGCAGGCCGACGCCCA CTCCACCCTG GCCAAGATC

As used herein, the term “CD3 zeta signaling domain” refers to aspecific protein fragment associated with this name and any othermolecules that have analogous biological function that share at least70%, or alternatively at least 80% amino acid sequence identity, oralternatively 90% sequence identity, or alternatively at least 95%sequence identity with the CD3 zeta signaling domain sequence as shownherein. The example sequences of the CD3 zeta signaling domain areprovided in U.S. application Ser. No. 13/826,258 (published as US2013/0266551). The sequence associated with the CD3 zeta signalingdomain is listed as follows (SEQ ID NO: 41):RVKFSRSADAPAYQQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQ ALPPR, andequivalents thereof.

As used herein, the term “T cell,” refers to a type of lymphocyte thatmatures in the thymus. T cells play an important role in cell-mediatedimmunity and are distinguished from other lymphocytes, such as B cells,by the presence of a T-cell receptor on the cell surface.

As used herein, the term “NK cell,” also known as natural killer cell,refers to a type of lymphocyte that originates in the bone marrow andplay a critical role in the innate immune system. NK cells provide rapidimmune responses against viral-infected cells, tumor cells or otherstressed cell, even in the absence of antibodies and majorhistocompatibility complex on the cell surfaces.

As used herein, the terms “nucleic acid sequence” and “polynucleotide”are used interchangeably to refer to a polymeric form of nucleotides ofany length, either ribonucleotides or deoxyribonucleotides. Thus, thisterm includes, but is not limited to, single-, double-, ormulti-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or apolymer comprising purine and pyrimidine bases or other natural,chemically or biochemically modified, non-natural, or derivatizednucleotide bases.

The term “encode” as it is applied to nucleic acid sequences refers to apolynucleotide which is said to “encode” a polypeptide if, in its nativestate or when manipulated by methods well known to those skilled in theart, can be transcribed and/or translated to produce the mRNA for thepolypeptide and/or a fragment thereof. The antisense strand is thecomplement of such a nucleic acid, and the encoding sequence can bededuced therefrom.

As used herein, the term signal peptide or signal polypeptide intends anamino acid sequence usually present at the N-terminal end of newlysynthesized secretory or membrane polypeptides or proteins. It acts todirect the polypeptide across or into a cell membrane and is thensubsequently removed. Examples of such are well known in the art.Non-limiting examples are those described in U.S. Pat. Nos. 8,853,381and 5,958,736.

As used herein, the term “vector” refers to a nucleic acid constructdeigned for transfer between different hosts, including but not limitedto a plasmid, a virus, a cosmid, a phage, a BAC, a YAC, etc. In someembodiments, plasmid vectors may be prepared from commercially availablevectors. In other embodiments, viral vectors may be produced frombaculoviruses, retroviruses, adenoviruses, AAVs, etc. according totechniques known in the art. In one embodiment, the viral vector is alentiviral vector.

As used herein, the term “isolated cell” generally refers to a cell thatis substantially separated from other cells of a tissue. The termincludes prokaryotic and eukaryotic cells.

“Immune cells” includes, e.g., white blood cells (leukocytes) which arederived from hematopoietic stem cells (HSC) produced in the bone marrow,lymphocytes (T cells, B cells, natural killer (NK) cells) andmyeloid-derived cells (neutrophil, eosinophil, basophil, monocyte,macrophage, dendritic cells). “T cell” includes all types of immunecells expressing CD3 including T-helper cells (CD4+ cells), cytotoxicT-cells (CD8+ cells), natural killer T-cells, T-regulatory cells (Treg)and gamma-delta T cells. A “cytotoxic cell” includes CD8+ T cells,natural-killer (NK) cells, and neutrophils, which cells are capable ofmediating cytotoxicity responses.

The term “transduce” or “transduction” as it is applied to theproduction of chimeric antigen receptor cells refers to the processwhereby a foreign nucleotide sequence is introduced into a cell. In someembodiments, this transduction is done via a vector.

As used herein, the term “autologous,” in reference to cells refers tocells that are isolated and infused back into the same subject(recipient or host). “Allogeneic” refers to non-autologous cells.

An “effective amount” or “efficacious amount” refers to the amount of anagent (e.g., a HLA-DR CAR cell), or combined amounts of two or moreagents, that, when administered for the treatment of a mammal or othersubject, is sufficient to effect such treatment for the disease.

The “effective amount” will vary depending on the agent(s), the diseaseand its severity and the age, weight, etc., of the subject to betreated.

A “solid tumor” is an abnormal mass of tissue that usually does notcontain cysts or liquid areas. Solid tumors can be benign or malignant.Different types of solid tumors are named for the type of cells thatform them. Examples of solid tumors include sarcomas, carcinomas, andlymphomas.

The term “B cell lymphoma or leukemia” refers to a type of cancer thatforms in issues of the lymphatic system or bone marrow, and hasundergone a malignant transformation that makes the cells within thecancer pathological to the host organism with the ability to invade orspread to other parts of the body.

As used herein, the term “comprising” is intended to mean that thecompositions and methods include the recited elements, but do notexclude others. “Consisting essentially of” when used to definecompositions and methods, shall mean excluding other elements of anyessential significance to the combination for the intended use. Forexample, a composition consisting essentially of the elements as definedherein would not exclude trace contaminants from the isolation andpurification method and pharmaceutically acceptable carriers, such asphosphate buffered saline, preservatives and the like. “Consisting of”shall mean excluding more than trace elements of other ingredients andsubstantial method steps for administering the compositions disclosedherein. Aspects defined by each of these transition terms are within thescope of the present disclosure.

As used herein, the term “detectable marker” refers to at least onemarker capable of directly or indirectly, producing a detectable signal.A non-exhaustive list of this marker includes enzymes which produce adetectable signal, for example by colorimetry, fluorescence,luminescence, such as horseradish peroxidase, alkaline phosphatase,β-galactosidase, glucose-6-phosphate dehydrogenase, chromophores such asfluorescent, luminescent dyes, groups with electron density detected byelectron microscopy or by their electrical property such asconductivity, amperometry, voltammetry, impedance, detectable groups,for example whose molecules are of sufficient size to induce detectablemodifications in their physical and/or chemical properties, suchdetection may be accomplished by optical methods such as diffraction,surface plasmon resonance, surface variation, the contact angle changeor physical methods such as atomic force spectroscopy, tunnel effect, orradioactive molecules such as ³²P, ³⁵S or ¹²⁵I.

As used herein, the term “purification marker” refers to at least onemarker useful for purification or identification. A non-exhaustive listof this marker includes His, lacZ, GST, maltose-binding protein, NusA,BCCP, c-myc, CaM, FLAG, GFP, YFP, cherry, thioredoxin, poly(NANP), V5,Snap, HA, chitin-binding protein, Softag 1, Softag 3, Strep, orS-protein. Suitable direct or indirect fluorescence marker compriseFLAG, GFP, YFP, RFP, dTomato, cherry, Cy3, Cy 5, Cy 5.5, Cy 7, DNP,AMCA, Biotin, Digoxigenin, Tamra, Texas Red, rhodamine, Alexa fluors,FITC, TRITC or any other fluorescent dye or hapten.

As used herein, the term “expression” refers to the process by whichpolynucleotides are transcribed into mRNA and/or the process by whichthe transcribed mRNA is subsequently being translated into peptides,polypeptides, or proteins. If the polynucleotide is derived from genomicDNA, expression may include splicing of the mRNA in a eukaryotic cell.The expression level of a gene may be determined by measuring the amountof mRNA or protein in a cell or tissue sample. In one aspect, theexpression level of a gene from one sample may be directly compared tothe expression level of that gene from a control or reference sample. Inanother aspect, the expression level of a gene from one sample may bedirectly compared to the expression level of that gene from the samesample following administration of a compound.

As used herein, “homology” or “identical”, percent “identity” or“similarity”, when used in the context of two or more nucleic acids orpolypeptide sequences, refers to two or more sequences or subsequencesthat are the same or have a specified percentage of nucleotides or aminoacid residues that are the same, e.g., at least 60% identity, preferablyat least 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,97%, 98%, 99%, or higher identity over a specified region (e.g.,nucleotide sequence encoding an antibody described herein or amino acidsequence of an antibody described herein). Homology can be determined bycomparing a position in each sequence which may be aligned for purposesof comparison. When a position in the compared sequence is occupied bythe same base or amino acid, then the molecules are homologous at thatposition. A degree of homology between sequences is a function of thenumber of matching or homologous positions shared by the sequences. Thealignment and the percent homology or sequence identity can bedetermined using software programs known in the art, for example thosedescribed in Current Protocols in Molecular Biology (Ausubel et al.,eds. 1987) Supplement 30, section 7.7.18, Table 7.7.1. Preferably,default parameters are used for alignment. A preferred alignment programis BLAST, using default parameters. In particular, preferred programsare BLASTN and BLASTP, using the following default parameters: Geneticcode=standard; filter=none; strand=both; cutoff=60; expect=10;Matrix=BLOSUM62; Descriptions=50 sequences; sort by=HIGH SCORE;Databases=non-redundant, GenBank+EMBL+DDBJ+PDB+GenBank CDStranslations+SwissProtein+SPupdate+PIR. Details of these programs can befound at the following Internet address: ncbi.nlm.nih.gov/cgi-bin/BLAST.The terms “homology” or “identical,” percent “identity” or “similarity”also refer to, or can be applied to, the complement of a test sequence.The terms also include sequences that have deletions and/or additions,as well as those that have substitutions. As described herein, thepreferred algorithms can account for gaps and the like. Preferably,identity exists over a region that is at least about 25 amino acids ornucleotides in length, or more preferably over a region that is at least50-100 amino acids or nucleotides in length. An “unrelated” or“non-homologous” sequence shares less than 40% identity, oralternatively less than 25% identity, with one of the sequencesdisclosed herein.

The phrase “first line” or “second line” or “third line” refers to theorder of treatment received by a patient. First line therapy regimensare treatments given first, whereas second or third line therapy aregiven after the first line therapy or after the second line therapy,respectively. The National Cancer Institute defines first line therapyas “the first treatment for a disease or condition. In patients withcancer, primary treatment can be surgery, chemotherapy, radiationtherapy, or a combination of these therapies. First line therapy is alsoreferred to those skilled in the art as “primary therapy and primarytreatment.” See National Cancer Institute website at www.cancer.gov,last visited on May 1, 2008. Typically, a patient is given a subsequentchemotherapy regimen because the patient did not show a positiveclinical or sub-clinical response to the first line therapy or the firstline therapy has stopped.

In one aspect, the term “equivalent” or “biological equivalent” of anantibody means the ability of the antibody to selectively bind itsepitope protein or fragment thereof as measured by ELISA or othersuitable methods. Biologically equivalent antibodies include, but arenot limited to, those antibodies, peptides, antibody fragments, antibodyvariant, antibody derivative and antibody mimetics that bind to the sameepitope as the reference antibody.

It is to be inferred without explicit recitation and unless otherwiseintended, that when the present disclosure relates to a polypeptide,protein, polynucleotide, antibody or fragment thereof, an equivalent ora biologically equivalent of such is intended within the scope of thisdisclosure. As used herein, the term “biological equivalent thereof” isintended to be synonymous with “equivalent thereof” when referring to areference protein, antibody or fragment thereof, polypeptide or nucleicacid, intends those having minimal homology while still maintainingdesired structure or functionality. Unless specifically recited herein,it is contemplated that any of the above also includes equivalentsthereof. For example, an equivalent intends at least about 70% homologyor identity, or at least 80% homology or identity and alternatively, orat least about 85%, or alternatively at least about 90%, oralternatively at least about 95%, or alternatively at least 98% percenthomology or identity and exhibits substantially equivalent biologicalactivity to the reference protein, polypeptide, antibody or fragmentthereof or nucleic acid. Alternatively, when referring topolynucleotides, an equivalent thereof is a polynucleotide thathybridizes under stringent conditions to the reference polynucleotide orits complement. Alternatively, when referring to polypeptides orproteins, an equivalent thereof is a expressed polypeptide or proteinfrom a polynucleotide that hybridizes under stringent conditions to thepolynucleotide or its complement that encodes the reference polypeptideor protein.

A polynucleotide or polynucleotide region (or a polypeptide orpolypeptide region) having a certain percentage (for example, 80%, 85%,90%, or 95%) of “sequence identity” to another sequence means that, whenaligned, that percentage of bases (or amino acids) are the same incomparing the two sequences. The alignment and the percent homology orsequence identity can be determined using software programs known in theart, for example those described in Current Protocols in MolecularBiology (Ausubel et al., eds. 1987) Supplement 30, section 7.7.18, Table7.7.1. Preferably, default parameters are used for alignment. Apreferred alignment program is BLAST, using default parameters. Inparticular, preferred programs are BLASTN and BLASTP, using thefollowing default parameters: Genetic code=standard; filter=none;strand=both; cutoff=60; expect=10; Matrix=BLOSUM62; Descriptions=50sequences; sort by=HIGH SCORE; Databases=non-redundant,GenBank+EMBL+DDBJ+PDB+GenBank CDStranslations+SwissProtein+SPupdate+PIR. Details of these programs can befound at the following Internet address: ncbi.nlm.nih.gov/cgi-bin/BLAST.

“Hybridization” refers to a reaction in which one or morepolynucleotides react to form a complex that is stabilized via hydrogenbonding between the bases of the nucleotide residues. The hydrogenbonding may occur by Watson-Crick base pairing, Hoogstein binding, or inany other sequence-specific manner. The complex may comprise two strandsforming a duplex structure, three or more strands forming amulti-stranded complex, a single self-hybridizing strand, or anycombination of these. A hybridization reaction may constitute a step ina more extensive process, such as the initiation of a PCR reaction, orthe enzymatic cleavage of a polynucleotide by a ribozyme.

Examples of stringent hybridization conditions include: incubationtemperatures of about 25° C. to about 37° C.; hybridization bufferconcentrations of about 6×SSC to about 10×SSC; formamide concentrationsof about 0% to about 25%; and wash solutions from about 4×SSC to about8×SSC. Examples of moderate hybridization conditions include: incubationtemperatures of about 40° C. to about 50° C.; buffer concentrations ofabout 9×SSC to about 2×SSC; formamide concentrations of about 30% toabout 50%; and wash solutions of about 5×SSC to about 2×SSC. Examples ofhigh stringency conditions include: incubation temperatures of about 55°C. to about 68° C.; buffer concentrations of about 1×SSC to about0.1×SSC; formamide concentrations of about 55% to about 75%; and washsolutions of about 1×SSC, 0.1×SSC, or deionized water. In general,hybridization incubation times are from 5 minutes to 24 hours, with 1,2, or more washing steps, and wash incubation times are about 1, 2, or15 minutes. SSC is 0.15 M NaCl and 15 mM citrate buffer. It isunderstood that equivalents of SSC using other buffer systems can beemployed.

A “normal cell corresponding to the tumor tissue type” refers to anormal cell from a same tissue type as the tumor tissue. A non-limitingexample is a normal lung cell from a patient having lung tumor, or anormal colon cell from a patient having colon tumor.

The term “isolated” as used herein refers to molecules or biologicals orcellular materials being substantially free from other materials. In oneaspect, the term “isolated” refers to nucleic acid, such as DNA or RNA,or protein or polypeptide (e.g., an antibody or derivative thereof), orcell or cellular organelle, or tissue or organ, separated from otherDNAs or RNAs, or proteins or polypeptides, or cells or cellularorganelles, or tissues or organs, respectively, that are present in thenatural source. The term “isolated” also refers to a nucleic acid orpeptide that is substantially free of cellular material, viral material,or culture medium when produced by recombinant DNA techniques, orchemical precursors or other chemicals when chemically synthesized.Moreover, an “isolated nucleic acid” is meant to include nucleic acidfragments which are not naturally occurring as fragments and would notbe found in the natural state. The term “isolated” is also used hereinto refer to polypeptides which are isolated from other cellular proteinsand is meant to encompass both purified and recombinant polypeptides.The term “isolated” is also used herein to refer to cells or tissuesthat are isolated from other cells or tissues and is meant to encompassboth cultured and engineered cells or tissues.

As used herein, the term “monoclonal antibody” refers to an antibodyproduced by a single clone of B-lymphocytes or by a cell into which thelight and heavy chain genes of a single antibody have been transfected.Monoclonal antibodies are produced by methods known to those of skill inthe art, for instance by making hybrid antibody-forming cells from afusion of myeloma cells with immune spleen cells. Monoclonal antibodiesinclude humanized monoclonal antibodies.

The term “protein”, “peptide” and “polypeptide” are used interchangeablyand in their broadest sense to refer to a compound of two or moresubunit amino acids, amino acid analogs or peptidomimetics. The subunitsmay be linked by peptide bonds. In another aspect, the subunit may belinked by other bonds, e.g., ester, ether, etc. A protein or peptidemust contain at least two amino acids and no limitation is placed on themaximum number of amino acids which may comprise a protein's orpeptide's sequence. As used herein the term “amino acid” refers toeither natural and/or unnatural or synthetic amino acids, includingglycine and both the D and L optical isomers, amino acid analogs andpeptidomimetics.

The terms “polynucleotide” and “oligonucleotide” are usedinterchangeably and refer to a polymeric form of nucleotides of anylength, either deoxyribonucleotides or ribonucleotides or analogsthereof. Polynucleotides can have any three-dimensional structure andmay perform any function, known or unknown. The following arenon-limiting examples of polynucleotides: a gene or gene fragment (forexample, a probe, primer, EST or SAGE tag), exons, introns, messengerRNA (mRNA), transfer RNA, ribosomal RNA, RNAi, ribozymes, cDNA,recombinant polynucleotides, branched polynucleotides, plasmids,vectors, isolated DNA of any sequence, isolated RNA of any sequence,nucleic acid probes and primers. A polynucleotide can comprise modifiednucleotides, such as methylated nucleotides and nucleotide analogs. Ifpresent, modifications to the nucleotide structure can be impartedbefore or after assembly of the polynucleotide. The sequence ofnucleotides can be interrupted by non-nucleotide components. Apolynucleotide can be further modified after polymerization, such as byconjugation with a labeling component. The term also refers to bothdouble- and single-stranded molecules. Unless otherwise specified orrequired, any aspect of this technology that is a polynucleotideencompasses both the double-stranded form and each of two complementarysingle-stranded forms known or predicted to make up the double-strandedform.

As used herein, the term “purified” does not require absolute purity;rather, it is intended as a relative term. Thus, for example, a purifiednucleic acid, peptide, protein, biological complexes or other activecompound is one that is isolated in whole or in part from proteins orother contaminants. Generally, substantially purified peptides,proteins, biological complexes, or other active compounds for use withinthe disclosure comprise more than 80% of all macromolecular speciespresent in a preparation prior to admixture or formulation of thepeptide, protein, biological complex or other active compound with apharmaceutical carrier, excipient, buffer, absorption enhancing agent,stabilizer, preservative, adjuvant or other co-ingredient in a completepharmaceutical formulation for therapeutic administration. Moretypically, the peptide, protein, biological complex or other activecompound is purified to represent greater than 90%, often greater than95% of all macromolecular species present in a purified preparationprior to admixture with other formulation ingredients. In other cases,the purified preparation may be essentially homogeneous, wherein othermacromolecular species are not detectable by conventional techniques.

As used herein, the term “specific binding” means the contact between anantibody and an antigen with a binding affinity of at least 10⁻⁶ M. Incertain aspects, antibodies bind with affinities of at least about10⁻⁷M, and preferably 10⁻⁸ M, 10⁻⁹ M, 10⁻¹⁰ M, 10⁻¹¹ M, or 10⁻¹² M.

As used herein, the term “recombinant protein” refers to a polypeptidewhich is produced by recombinant DNA techniques, wherein generally, DNAencoding the polypeptide is inserted into a suitable expression vectorwhich is in turn used to transform a host cell to produce theheterologous protein.

As used herein, “treating” or “treatment” of a disease in a subjectrefers to (1) preventing the symptoms or disease from occurring in asubject that is predisposed or does not yet display symptoms of thedisease; (2) inhibiting the disease or arresting its development; or (3)ameliorating or causing regression of the disease or the symptoms of thedisease. As understood in the art, “treatment” is an approach forobtaining beneficial or desired results, including clinical results. Forthe purposes of the present technology, beneficial or desired resultscan include one or more, but are not limited to, alleviation oramelioration of one or more symptoms, diminishment of extent of acondition (including a disease), stabilized (i.e., not worsening) stateof a condition (including disease), delay or slowing of condition(including disease), progression, amelioration or palliation of thecondition (including disease), states and remission (whether partial ortotal), whether detectable or undetectable. When the disease is cancer,the following clinical end points are non-limiting examples oftreatment: reduction in tumor burden, slowing of tumor growth, longeroverall survival, longer time to tumor progression, inhibition ofmetastasis or a reduction in metastasis of the tumor.

As used herein, the term “overexpress” with respect to a cell, a tissue,or an organ expresses a protein to an amount that is greater than theamount that is produced in a control cell, a control issue, or an organ.A protein that is overexpressed may be endogenous to the host cell orexogenous to the host cell.

As used herein the term “linker sequence” relates to any amino acidsequence comprising from 1 to 10, or alternatively, 8 amino acids, oralternatively 6 amino acids, or alternatively 5 amino acids that may berepeated from 1 to 10, or alternatively to about 8, or alternatively toabout 6, or alternatively about 5, or 4 or alternatively 3, oralternatively 2 times. For example, the linker may comprise up to 15amino acid residues consisting of a pentapeptide repeated three times.Non-limiting examples of linker sequences are known in the art, e.g.,GGGGSGGGGSGGGG (and equivalents thereof) (SEQ ID NO: 49); the tripeptideEFM; or Glu-Phe-Gly-Ala-Gly-Leu-Val-Leu-Gly-Gly-Gln-Phe-Met (SEQ ID NO:50), and equivalents of each thereof. In one aspect, the linker sequenceis a (Glycine4Serine)3 flexible polypeptide linker (SEQ ID NO: 51)comprising three copies of gly-gly-gly-gly-ser (SEQ ID NO: 52), andequivalents thereof.

As used herein, the term “enhancer”, as used herein, denotes sequenceelements that augment, improve or ameliorate transcription of a nucleicacid sequence irrespective of its location and orientation in relationto the nucleic acid sequence to be expressed. An enhancer may enhancetranscription from a single promoter or simultaneously from more thanone promoter. As long as this functionality of improving transcriptionis retained or substantially retained (e.g., at least 70%, at least 80%,at least 90% or at least 95% of wild-type activity, that is, activity ofa full-length sequence), any truncated, mutated or otherwise modifiedvariants of a wild-type enhancer sequence are also within the abovedefinition.

The term “promoter” as used herein refers to any sequence that regulatesthe expression of a coding sequence, such as a gene. Promoters may beconstitutive, inducible, repressible, or tissue-specific, for example. A“promoter” is a control sequence that is a region of a polynucleotidesequence at which initiation and rate of transcription are controlled.It may contain genetic elements at which regulatory proteins andmolecules may bind such as RNA polymerase and other transcriptionfactors.

As used herein, the term “WPRE” or “Woodchuck Hepatitis Virus (WHP)Post-transcriptional Regulatory Element” refers to a specific nucleotidefragment associated with this name and any other molecules that haveanalogous biological function that share at least 70%, or alternativelyat least 80% amino acid sequence identity, preferably 90% sequenceidentity, more preferably at least 95% sequence identity with the WPREsequence as shown herein. For example, WPRE refers to a region similarto the human hepatitis B virus posttranscriptional regulatory element(HBVPRE) present in the Woodchuck hepatitis virus genomic sequence(GenBank Accession No. J04514), and that the 592 nucleotides fromposition 1093 to 1684 of this genomic sequence correspond to thepost-transcriptional regulatory region (Donello, J. E. et al. (1998)Journal of Virology 72:5085-5092). The analysis using retroviral vectorsrevealed that WPRE inserted into the 3′-terminal untranslated region ofa gene of interest increases the amount of protein produced by 5 to 8folds. It has also been reported that the introduction of WPREsuppresses mRNA degradation (Zufferey, R. et al. (1999) Journal ofVirology 73:2886-2892). In a broad sense, elements such as WPRE thatincrease the efficiency of amino acid translation by stabilizing mRNAsare also thought to be enhancers.

List of Abbreviations

CAR: chimeric antigen receptorHLA: histocompatibility lymphocyte antigenIp: intraperitonealIRES: internal ribosomal entry siteMFI: mean fluorescence intensityMOI: multiplicity of infectionPBMC: peripheral blood mononuclear cellsPBS: phosphate buffered salinescFv: single chain variable fragmentWPRE: woodchuck hepatitis virus post-transcriptional regulatory element

MODES FOR CARRYING OUT THE DISCLOSURE

Due to the unprecedented results being recently obtained in B-celllymphomas and leukemia's using autologous treatment with geneticallyengineered chimeric antigen receptor (CAR) T-cells (Maude, S. L. et al.(2014) New Engl. J. Med. 371:1507-1517; Porter, D. L. et al. (2011) NewEngl. J. Med. 365:725-733), a number of laboratories have begun to applythis approach to solid tumors including ovarian cancer, prostate cancer,and pancreatic tumors. CAR modified T-cells combine the HLA-independenttargeting specificity of a monoclonal antibody with the cytolyticactivity, proliferation, and homing properties of activated T-cells, butdo not respond to checkpoint suppression. Because of their ability tokill antigen expressing targets directly, CAR T-cells are highly toxicto any antigen positive cells or tissues making it a requirement toconstruct CARs with highly tumor specific antibodies. To date, CARmodified T-cells to human solid tumors have been constructed against theα-folate receptor, mesothelin, and MUC-CD, PSMA, and other targets butmost have some off-target expression of antigen in normal tissues. Theseconstructs have not shown the same exceptional results in patientsemphasizing the need for additional studies to identify new targets andmethods of CAR T-cell construction that can be used against solidtumors.

Thus, this disclosure provides antibodies specific to HLA-DR and methodsand compositions relating to the use and production thereof. Inaddition, this disclosure provides as a chimeric antigen receptor (CAR)comprising an antigen binding domain specific to HLA-DR, that in someaspects, is the antigen binding domain of Lym-1 and Lym-2 antibodies andmethods and compositions relating to the use and production thereof.

Antibodies and Uses Thereof

I. Compositions

The general structure of antibodies is known in the art and will only bebriefly summarized here. An immunoglobulin monomer comprises two heavychains and two light chains connected by disulfide bonds. Each heavychain is paired with one of the light chains to which it is directlybound via a disulfide bond. Each heavy chain comprises a constant region(which varies depending on the isotype of the antibody) and a variableregion. The variable region comprises three hypervariable regions (orcomplementarity determining regions) which are designated CDRH1, CDRH2and CDRH3 and which are supported within framework regions. Each lightchain comprises a constant region and a variable region, with thevariable region comprising three hypervariable regions (designatedCDRL1, CDRL2 and CDRL3) supported by framework regions in an analogousmanner to the variable region of the heavy chain.

The hypervariable regions of each pair of heavy and light chainsmutually cooperate to provide an antigen binding site that is capable ofbinding a target antigen. The binding specificity of a pair of heavy andlight chains is defined by the sequence of CDR1, CDR2 and CDR3 of theheavy and light chains. Thus once a set of CDR sequences (i.e., thesequence of CDR1, CDR2 and CDR3 for the heavy and light chains) isdetermined which gives rise to a particular binding specificity, the setof CDR sequences can, in principle, be inserted into the appropriatepositions within any other antibody framework regions linked with anyantibody constant regions in order to provide a different antibody withthe same antigen binding specificity.

In one aspect, the present disclosure provides an isolated antibodycomprising a heavy chain (HC) immunoglobulin variable domain sequenceand a light chain (LC) immunoglobulin variable domain sequence, whereinthe heavy chain and light chain immunoglobulin variable domain sequencesform an antigen binding site that binds to an epitope of human HLA-DR.

In some embodiments, the heavy chain variable region comprises a CDRH1sequence comprising, or alternatively consisting essentially of, or yetfurther consisting of, an amino acid sequence beginning with any one ofthe following sequences (i) GFSLTSYG (SEQ ID NO: 1), (ii) GFTFSNYW (SEQID NO: 2), or equivalents of each thereof, followed by an additional 50amino acids, or alternatively about 40 amino acids, or alternativelyabout 30 amino acids, or alternatively about 20 amino acids, oralternatively about 10 amino acids, or alternatively about 5 aminoacids, or alternatively about 4, or 3, or 2 or 1 amino acids at thecarboxy-terminus.

In some embodiments, the heavy chain variable region comprises a CDRH2sequence comprising, or alternatively consisting essentially of, or yetfurther consisting of, an amino acid sequence beginning with any one ofthe following sequences: (i) IWSDGST (SEQ ID NO: 3), (ii) IRFKSHNYAT(SEQ ID NO: 4), or equivalents of each thereof, followed by anadditional 50 amino acids, or alternatively about 40 amino acids, oralternatively about 30 amino acids, or alternatively about 20 aminoacids, or alternatively about 10 amino acids, or alternatively about 5amino acids, or alternatively about 4, or 3, or 2 or 1 amino acids atthe carboxy-terminus.

In some embodiments, the heavy chain variable region comprises a CDRH3sequence comprising, or alternatively consisting essentially of, or yetfurther consisting of, an amino acid sequence beginning with any one ofthe following sequences: (i) ASHYGSTLAFAS (SEQ ID NO: 5), (ii)TRRIGNSDYDWWYFDV (SEQ ID NO: 6), or equivalents of each thereof,followed by an additional 50 amino acids, or alternatively about 40amino acids, or alternatively about 30 amino acids, or alternativelyabout 20 amino acids, or alternatively about 10 amino acids, oralternatively about 5 amino acids, or alternatively about 4, or 3, or 2or 1 amino acids at the carboxy-terminus.

In some embodiments, the heavy chain variable region comprises, oralternatively consists essentially of, or yet further consists of, thepolypeptide encoded by the below noted polynucleotide sequence:CAGGTGCAGCTGAAGGAGTCAGGACCTGGCCTGGTGGCGCCCTCACAGAGCCTGTCCATCACATGCACCATCTCAGGGTTCTCATTAACCAGCTATGGTGTACACTGGGTTCGCCAGCCTCCAGGAAAGGGTCTGGAGTGGCTGGTAGTGATATGGAGTGATGGAAGCACAACCTATAATTCAGCTCTCAAATCCAGACTGAGCATCAGCAAGGACAACTCCAAGAGCCAAGTTTTCTTAAAAATGAACAGTCTCCAAACTGATGACACAGCCATATACTACTGTGCCAGTCACTACGGTAGTACCCTTGCCTTTGCTTCCTGGGGCCACGGGACTCTGGTCACTGTCTCTGCA (SEQ ID NO: 7), or an antigen binding fragment thereofor an equivalent of each thereof.

In some embodiments, the heavy chain variable region comprises, oralternatively consists essentially of, or yet further consists of, theamino acid sequence:QLKESGPGLVAPSQSLSITCTISGFSLTSYGVHWVRQPPGKGLEWLVVIWSDGSTTYNSALKSRLSISKDNSKSQVFLKMNSLQTDDTAIYYCASHYGSTLAFASWGHGTLVTVSA (SEQ ID NO: 8),or an antigen binding fragment thereof or an equivalent of each thereof.

In some embodiments, the heavy chain variable region comprises, oralternatively consists essentially of, or yet further consists of, thepolypeptide encoded by the below noted polynucleotide sequence:GAAGTGCAGCTTGAGGAGTCTGGAGGAGGCTTGGTGCAACCTGGAGGCTCCATGAAACTCTCCTGTGTTGCCTCTGGATTCACTTTCAGTAACTATTGGATGAACTGGGTCCGCCAGTCTCCAGAGAAGGGGCTTGAGTGGGTTGCTGAAATTAGATTTAAATCTCATAATTATGCAACACATTTTGCGGAGTCTGTGAAAGGGAGGTTCACCATCTCAAGAGATGATTCCAAAAGTAGTGTCTACCTGCAAATGAACAACTTAAGAGCTGAAGACACTGGCATTTATTACTGTACCAGGAGGATAGGAAACTCTGATTACGACTGGTGGTACTTCGATGTCTGGGGCGCAGGGACCTCAGTCACCGTCTCCTCAGCTAGC (SEQ ID NO: 9), or an antigenbinding fragment thereof or an equivalent of each thereof.

In some embodiments, the heavy chain variable region comprises, oralternatively consists essentially of, or yet further consists of, theamino acid sequence:EVQLEESGGGLVQPGGSMKLSCVASGFTFSNYWMNWVRQSPEKGLEWVAEIRFKSHNYATHFAESVKGRFTISRDDSKSSVYLQMNNLRAEDTGIYYCTRRIGNSDYDWWYFDVW GAGTSVTVSSAS(SEQ ID NO: 10), or an antigen binding fragment thereof or an equivalentof each thereof.

In some embodiments, the light chain variable region comprises a CDRL1sequence comprising, or alternatively consisting essentially of, or yetfurther consisting of, an amino acid sequence beginning with any one ofthe following sequences (i) VNIYSY (SEQ ID NO: 11), (ii) QNVGNN (SEQ IDNO: 12), or equivalents of each thereof, followed by an additional 50amino acids, or alternatively about 40 amino acids, or alternativelyabout 30 amino acids, or alternatively about 20 amino acids, oralternatively about 10 amino acids, or alternatively about 5 aminoacids, or alternatively about 4, or 3, or 2 or 1 amino acids at thecarboxy-terminus.

In some embodiments, the light chain variable region comprises a CDRL2sequence comprising, or alternatively consisting essentially of, or yetfurther consisting of, an amino acid sequence beginning with (i) NAK(SEQ ID NO: 13), (ii) SAS (SEQ ID NO: 14), or equivalents of eachthereof, followed by an additional 50 amino acids, or alternativelyabout 40 amino acids, or alternatively about 30 amino acids, oralternatively about 20 amino acids, or alternatively about 10 aminoacids, or alternatively about 5 amino acids, or alternatively about 4,or 3, or 2 or 1 amino acids at the carboxy-terminus.

In other embodiments, the light chain variable region comprises a CDRL3sequence comprising, or alternatively consisting essentially of, or yetfurther consisting of, an amino acid sequence beginning (i) QHHYGTFT(SEQ ID NO: 15), (ii) QQYNTYPFT (SEQ ID NO: 16), or equivalents of eachthereof, followed by an additional 50 amino acids, or alternativelyabout 40 amino acids, or alternatively about 30 amino acids, oralternatively about 20 amino acids, or alternatively about 10 aminoacids, or alternatively about 5 amino acids, or alternatively about 4,or 3, or 2 or 1 amino acids at the carboxy-terminus.

In some embodiments, the light chain variable region comprises, oralternatively consists essentially of, or yet further consists of, thepolypeptide encoded by the polynucleotide sequence:GACATCCAGATGACTCAGTCTCCAGCCTCCCTATCTGCATCTGTGGGAGAAACTGTCACCATCATATGTCGAGCAAGTGTGAATATTTACAGTTATTTAGCATGGTATCAGCAGAAACAGGGAAAATCTCCTCAGCTCCTGGTCTATAATGCCAAAATCTTAGCAGAAGGTGTGCCATCAAGGTTCAGTGGCAGTGGATCAGGCACACAGTTTTCTCTGAAGATCAACAGCCTGCAGCCTGAAGATTTTGGGAGTTATTACTGTCAACATCATTATGGTACATTCACGTTCGGCTCGGGGACAAAGTTGGAAATAAAA (SEQ ID NO: 17), or an antigen bindingfragment thereof or an equivalent of each thereof.

In some embodiments, the light chain variable region comprises, oralternatively consists essentially of, or yet further consists of, theamino acid sequence:DIQMTQSPASLSASVGETVTIICRASVNIYSYLAWYQQKQGKSPQLLVYNAKILAEGVPSRFSGSGSGTQFSLKINSLQPEDFGSYYCQHHYGTFTFGSGTKLEIK (SEQ ID NO: 18), or anantigen binding fragment thereof or an equivalent of each thereof.

In some embodiments, the light chain variable region comprises, oralternatively consists essentially of, or yet further consists of, thepolypeptide encoded by the polynucleotide sequence:GACATTGTGATGACCCAGTCTCACAAATTCATGTCCACATCAGTAGGAGACAGGGTCAGCGTCACCTGCAAGGCCAGTCAGAATGTGGGTAATAATGTAGCCTGGTATCAACAGAAACCAGGGCAATCTCCTAAAGTACTGATTTACTCGGCATCCTACCGGTACAGTGGAGTCCCTGATCGCTTCACAGGCAGTGGATCTGGGACAGATTTCACTCTCACCATCAGTAATGTGCAGTCTGAAGACTTGGCAGAGTATTTCTGTCAGCAATATAACACCTATCCATTCACGTTCGGCTCGGGGACAAAGTTGGAAATAAAA (SEQ ID NO: 19), or an antigenbinding fragment thereof or an equivalent of each thereof.

In some embodiments, the light chain variable region comprises, oralternatively consists essentially of, or yet further consists of, theamino acid sequence:DIVMTQSHKFMSTSVGDRVSVTCKASQNVGNNVAWYQQKPGQSPKVLIYSASYRYSGVPDRFTGSGSGTDFTLTISNVQSEDLAEYFCQQYNTYPFTFGSGTKLEIK (SEQ ID NO: 20), oran antigen binding fragment thereof or an equivalent of each thereof.

In another aspect of the present technology, the isolated antibodyincludes one or more of the following characteristics:

(a) the light chain immunoglobulin variable domain sequence comprisesone or more CDRs that are at least 85% identical to a CDR of a lightchain variable domain of any of the disclosed light chain sequences;

(b) the heavy chain immunoglobulin variable domain sequence comprisesone or more CDRs that are at least 85% identical to a CDR of a heavychain variable domain of any of the disclosed heavy chain sequences;

(c) the light chain immunoglobulin variable domain sequence is at least85% identical to a light chain variable domain of any of the disclosedlight chain sequences;

(d) the HC immunoglobulin variable domain sequence is at least 85%identical to a heavy chain variable domain of any of the disclosed lightchain sequences; and

(e) the antibody binds an epitope that overlaps with an epitope bound byany of the disclosed sequences.

Exemplary antibodies comprising the disclosed CDR sequences and heavyand light chain variable sequences are disclosed in Table 1 and Table 2,respectively.

TABLE 1 ANTIBODY CDRH1 CDRH2 CDRH3 CDRL1 CDRL2 CDRL3 Lym-1 SEQ ID NO: 1SEQ ID NO: 3 SEQ ID NO: 5 SEQ ID NO: 11 SEQ ID NO: 13 SEQ ID NO: 15Lym-2 SEQ ID NO: 2 SEQ ID: NO 4 SEQ ID: NO 6 SEQ ID NO: 12 SEQ ID NO: 14SEQ ID NO: 16

TABLE 2 Heavy Chain Light Chain ANTIBODY Variable Region Variable RegionLym-1 SEQ ID NO: 7 and 8 SEQ ID NO: 17 and 18 Lym-2 SEQ ID NO: 9 and 10SEQ ID NO: 19 and 20

In one aspect, the present disclosure provides an isolated antibody thatis at least 85% identical to an antibody selected from the groupconsisting of Lym-1 and Lym-2.

In one aspect, the present disclosure provides an isolated antibodycomprising the CDRs of Lym-1. In one aspect, the present disclosureprovides an isolated antibody that is at least 85% identical to Lym-1.

In one aspect, the present disclosure provides an isolated antibodycomprising the CDRs of Lym-2. In one aspect, the present disclosureprovides an isolated antibody that is at least 85% identical to Lym-2.

In some aspects of the antibodies provided herein, the HC variabledomain sequence comprises, or consists essentially of, or yet furtherconsists of, a variable domain sequence of Lym-1 and the LC variabledomain sequence comprises, or consists essentially of, or yet furtherconsists of a variable domain sequence of Lym-1.

In some aspects of the antibodies provided herein, the HC variabledomain sequence comprises, or consists essentially of, or yet furtherconsists of, a variable domain sequence of Lym-2 and the LC variabledomain sequence comprises, or consists essentially of, or yet furtherconsists of a variable domain sequence of Lym-2.

In some of the aspects of the antibodies provided herein, the antibodybinds human HLA-DR with a dissociation constant (K_(D)) of less than10⁻⁴M, 10⁻⁵M, 10⁻⁶M, 10⁻⁷M, 10⁻⁸M, 10⁻⁹M, 10⁻¹⁰ M, 10⁻¹¹ M, or 10⁻¹²M.In some of the aspects of the antibodies provided herein, the antigenbinding site specifically binds to human HLA-DR.

In some of the aspects of the antibodies provided herein, the antibodyis soluble Fab.

In some of the aspects of the antibodies provided herein, the HC and LCvariable domain sequences are components of the same polypeptide chain.In some of the aspects of the antibodies provided herein, the HC and LCvariable domain sequences are components of different polypeptidechains.

In some of the aspects of the antibodies provided herein, the antibodyis a full-length antibody.

In some of the aspects of the antibodies provided herein, the antibodyis a monoclonal antibody.

In some of the aspects of the antibodies provided herein, the antibodyis chimeric or humanized.

In some of the aspects of the antibodies provided herein, the antibodyis selected from the group consisting of Fab, F(ab)′2, Fab′, scF_(v),and F_(v).

In some of the aspects of the antibodies provided herein, the antibodycomprises an Fc domain. In some of the aspects of the antibodiesprovided herein, the antibody is a rabbit antibody. In some of theaspects of the antibodies provided herein, the antibody is a human orhumanized antibody or is non-immunogenic in a human.

In some of the aspects of the antibodies provided herein, the antibodycomprises a human antibody framework region.

In other aspects, one or more amino acid residues in a CDR of theantibodies provided herein are substituted with another amino acid. Thesubstitution may be “conservative” in the sense of being a substitutionwithin the same family of amino acids. The naturally occurring aminoacids may be divided into the following four families and conservativesubstitutions will take place within those families.

1) Amino acids with basic side chains: lysine, arginine, histidine.

2) Amino acids with acidic side chains: aspartic acid, glutamic acid

3) Amino acids with uncharged polar side chains: asparagine, glutamine,serine, threonine, tyrosine.

4) Amino acids with nonpolar side chains: glycine, alanine, valine,leucine, isoleucine, proline, phenylalanine, methionine, tryptophan,cysteine.

In another aspect, one or more amino acid residues are added to ordeleted from one or more CDRs of an antibody. Such additions ordeletions occur at the N or C termini of the CDR or at a position withinthe CDR.

By varying the amino acid sequence of the CDRs of an antibody byaddition, deletion or substitution of amino acids, various effects suchas increased binding affinity for the target antigen may be obtained.

It is to be appreciated that antibodies of the present disclosurecomprising such varied CDR sequences still bind HLA-DR with similarspecificity and sensitivity profiles as the disclosed antibodies. Thismay be tested by way of the binding assays known to skill in the art andbriefly described herein.

The constant regions of antibodies can also be varied. For example,antibodies are provided with Fc regions of any isotype: IgA (IgA1,IgA2), IgD, IgE, IgG (IgG1, IgG2, IgG3, IgG4) or IgM. Non-limitingexamples of constant region sequences include:

Human IgD constant region, Uniprot: P01880 (SEQ ID NO: 21)APTKAPDVFPIISGCRHPKDNSPVVLACLITGYHPTSVTVTWYMGTQSQPQRTFPEIQRRDSYYMTSSQLSTPLQQWRQGEYKCVVQHTASKSKKEIFRWPESPKAQASSVPTAQPQAEGSLAKATTAPATTRNTGRGGEEKKKEKEKEEQEERETKTPECPSHTQPLGVYLLTPAVQDLWLRDKATFTCFVVGSDLKDAHLTWEVAGKVPTGGVEEGLLERHSNGSQSQHSRLTLPRSLWNAGTSVTCTLNHPSLPPQRLMALREPAAQAPVKLSLNLLASSDPPEAASWLLCEVSGESPPNILLMWLEDQREVNTSGFAPARPPPQPGSTTFWAWSVLRVPAPPSPQPATYTCVVSHEDSRTLLNASRSLEVSYVTDHGPMK, and equivalents thereof.

Human IgG1 constant region, Uniprot: P01857 (SEQ ID NO: 22)ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLEPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK, and equivalents thereof.

Human IgG2 constant region, Uniprot: P01859 (SEQ ID NO: 23)ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVERKCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDISVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK, and equivalents thereof.

Human IgG3 constant region, Uniprot: P01860 (SEQ ID NO: 24)ASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSPGK, and equivalents thereof.

Human IgM constant region, Uniprot: P01871 (SEQ ID NO: 25)GSASAPTLFPLVSCENSPSDTSSVAVGCLAQDFLPDSITLSWKYKNNSDISSTRGFPSVLRGGKYAATSQVLLPSKDVMQGTDEHVVCKVQHPNGNKEKNVPLPVIAELPPKVSVFVPPRDGFFGNPRKSKLICQATGFSPRQIQVSWLREGKQVGSGVTTDQVQAEAKESGPTTYKVTSTLTIKESDWLGQSNIFTCRVDHRGLTFQQNASSMCVPDQDTAIRVFAIPPSFASIFLTKSTKLTCLVTDLTTYDSVTISWTRQNGEAVKTHTNISESHPNATFSAVGEASICEDDWNSGERFTCTVTHTDLPSPLKQTISRPKGVALHRPDVYLLPPAREQLNLRESATITCLVTGFSPADVFVQWMQRGQPLSPEKYVTSAPMPEPQAPGRYFAHSILTVSEEEWNTGETYTCVAHEALPNRVTERTVDKSTGKPTLYNVSLVMSDTAGTCY, and equivalents thereof.

Human IgG4 constant region, Uniprot: P01861 (SEQ ID NO: 26)ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK, and equivalents thereof.

Human IgA1 constant region, Uniprot: P01876 (SEQ ID NO: 27)ASPTSPKVFPLSLCSTQPDGNVVIACLVQGFFPQEPLSVTWSESGQGVTARNFPPSQDASGDLYTTSSQLTLPATQCLAGKSVTCHVKHYTNPSQDVTVPCPVPSTPPTPSPSTPPTPSPSCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASGVTFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAEPWNHGKTFTCTAAYPESKTPLTATLSKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRLAGKPTHVNVSVVMAEVDGTCY, and equivalentsthereof.

Human IgA2 constant region, Uniprot: P01877 (SEQ ID NO: 28)ASPTSPKVFPLSLDSTPQDGNVVVACLVQGFFPQEPLSVTWSESGQNVTARNFPPSQDASGDLYTTSSQLTLPATQCPDGKSVTCHVKHYTNPSQDVTVPCPVPPPPPCCHPRLSLHRPALEDLLLGSEANLTCTLTGLRDASGATFTWTPSSGKSAVQGPPERDLCGCYSVSSVLPGCAQPWNHGETFTCTAAHPELKTPLTANITKSGNTFRPEVHLLPPPSEELALNELVTLTCLARGFSPKDVLVRWLQGSQELPREKYLTWASRQEPSQGTTTFAVTSILRVAAEDWKKGDTFSCMVGHEALPLAFTQKTIDRMAGKPTHVNVSVVMAEVDGTCY, and equivalents thereof.

Human Ig kappa constant region, Uniprot: P01834 (SEQ ID NO: 29)TVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC, and equivalentsthereof.

In some aspects, the antibodies comprise a heavy chain constant regionthat is at least 80% identical to any one of SEQ ID NOs: 7 to 10.

In some aspects, the antibodies comprise a light chain constant regionthat is at least 80% identical to any one of SEQ ID NOs: 17 to 20.

In some aspects of the antibodies provided herein, the antibody binds tothe epitope bound by Lym-1 and Lym-2 antibodies.

In some aspects of the antibodies provided herein, the HLA-DR-specificantibody competes for binding to human HLA-DR with Lym-1 and Lym-2.

In some aspects of the antibodies provided herein, the antibody containsstructural modifications to facilitate rapid binding and cell uptakeand/or slow release. In some aspects, the HLA-DR antibody contains adeletion in the CH2 constant heavy chain region of the antibody tofacilitate rapid binding and cell uptake and/or slow release. In someaspects, a Fab fragment is used to facilitate rapid binding and celluptake and/or slow release. In some aspects, a F(ab)′2 fragment is usedto facilitate rapid binding and cell uptake and/or slow release.

The antibodies, fragments, and equivalents thereof can be combined witha carrier, e.g., a pharmaceutically acceptable carrier or other agentsto provide a formulation for use and/or storage.

Further provided is an isolated polypeptide comprising, or alternativelyconsisting essentially of, or yet further consisting of, the amino acidsequence of HLA-DR or a fragment thereof, that are useful to generateantibodies that bind to HLA-DR, as well as isolated polynucleotides thatencode them. In one aspect, the isolated polypeptides or polynucleotidesfurther comprise a label and/or contiguous polypeptide sequences (e.g.,keyhole limpet haemocyanin (KLH) carrier protein) or in the case ofpolynucleotides, polynucleotides encoding the sequence, operativelycoupled to polypeptide or polynucleotide. The polypeptides orpolynucleotides can be combined with various carriers, e.g., phosphatebuffered saline. Further provided are host cells, e.g., prokaryotic oreukaryotic cells, e.g., bacteria, yeast, mammalian (rat, simian,hamster, or human), comprising the isolated polypeptides orpolynucleotides. The host cells can be combined with a carrier.

II. Processes for Preparing Compositions

Antibodies, their manufacture and uses are well known and disclosed in,for example, Harlow, E. and Lane, D. (1999) Antibodies: A LaboratoryManual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.The antibodies may be generated using standard methods known in the art.Examples of antibodies include (but are not limited to) monoclonal,single chain, and functional fragments of antibodies. Methods forgenerating such antibodies are known in the art; see, e.g. Collarini etal. (2009) J. Immunol. 183(10):6338-6345.

Antibodies may be produced in a range of hosts, for example goats,rabbits, rats, mice, humans, and others. They may be immunized byinjection with a target antigen or a fragment or oligopeptide thereofwhich has immunogenic properties, such as a C-terminal fragment ofHLA-DR or an isolated polypeptide. Depending on the host species,various adjuvants may be added and used to increase an immunologicalresponse. Such adjuvants include, but are not limited to, Freund's,mineral gels such as aluminum hydroxide, and surface active substancessuch as lysolecithin, pluronic polyols, polyanions, peptides, oilemulsions, keyhole limpet hemocyanin, and dinitrophenol. Among adjuvantsused in humans, BCG (Bacille Calmette-Guerin) and Corynebacterium parvumare particularly useful. This this disclosure also provides the isolatedpolypeptide and an adjuvant.

In certain aspects, the antibodies of the present disclosure arepolyclonal, i.e., a mixture of plural types of anti-HLA-DR antibodieshaving different amino acid sequences. In one aspect, the polyclonalantibody comprises a mixture of plural types of anti-HLA-DR antibodieshaving different CDRs. As such, a mixture of cells which producedifferent antibodies is cultured, and an antibody purified from theresulting culture can be used (see International Patent ApplicationPublication No. WO 2004/061104).

Monoclonal Antibody Production. Monoclonal antibodies to HLA-DR may beprepared using any technique which provides for the production ofantibody molecules by continuous cell lines in culture. Such techniquesinclude, but are not limited to, the hybridoma technique (see, e.g.,Kohler, G. et al. (1975) Nature 256:495-497); the trioma technique; thehuman B-cell hybridoma technique (see, e.g., Kozbor, D. et al. (1983)Immunol. Today 4:72) and the EBV hybridoma technique to produce humanmonoclonal antibodies (see, e.g., Cole et al. (1985) in MonoclonalAntibodies and Cancer Therapy, Alan R. Liss, Inc., 77-96). Humanmonoclonal antibodies can be utilized in the practice of the presenttechnology and can be produced by using human hybridomas (see, e.g.,Cote, R. J. et al. (1983) Proc. Natl. Acad. Sci. U.S.A. 80:2026-2030) orby transforming human B-cells with Epstein Barr Virus in vitro (see,e.g., Cole et al. (1985) in Monoclonal Antibodies and Cancer Therapy,Alan R. Liss, Inc., 77-96). For example, a population of nucleic acidsthat encode regions of antibodies can be isolated. PCR utilizing primersderived from sequences encoding conserved regions of antibodies is usedto amplify sequences encoding portions of antibodies from the populationand then reconstruct DNAs encoding antibodies or fragments thereof, suchas variable domains, from the amplified sequences. Such amplifiedsequences also can be fused to DNAs encoding other proteins—e.g., abacteriophage coat, or a bacterial cell surface protein—for expressionand display of the fusion polypeptides on phage or bacteria. Amplifiedsequences can then be expressed and further selected or isolated based,e.g., on the affinity of the expressed antibody or fragment thereof foran antigen or epitope present on the HLA-DR polypeptide. Alternatively,hybridomas expressing anti-HLA-DR monoclonal antibodies can be preparedby immunizing a subject, e.g., with an isolated polypeptide comprising,or alternatively consisting essentially of, or yet further consistingof, the amino acid sequence of HLA-DR or a fragment thereof, and thenisolating hybridomas from the subject's spleen using routine methods.See, e.g., Galfre, G. et al. (1981) Methods Enzymol. 73:3-46. Screeningthe hybridomas using standard methods will produce monoclonal antibodiesof varying specificity (i.e., for different epitopes) and affinity. Aselected monoclonal antibody with the desired properties, e.g., HLA-DRbinding, can be (i) used as expressed by the hybridoma, (ii) bound to amolecule such as polyethylene glycol (PEG) to alter its properties, or(iii) a cDNA encoding the monoclonal antibody can be isolated, sequencedand manipulated in various ways. In one aspect, the anti-HLA-DRmonoclonal antibody is produced by a hybridoma which includes a B cellobtained from a transgenic non-human animal, e.g., a transgenic mouse,having a genome comprising a human heavy chain transgene and a lightchain transgene fused to an immortalized cell. Hybridoma techniquesinclude those known in the art and taught in Harlow et al. (1988)Antibodies: A Laboratory Manual Cold Spring Harbor Laboratory, ColdSpring Harbor, N.Y., 349; Hammerling et al. (1981) Monoclonal AntibodiesAnd T-Cell Hybridomas, 563-681.

Phage Display Technique. As noted above, the antibodies of the presentdisclosure can be produced through the application of recombinant DNAand phage display technology. For example, anti-HLA-DR antibodies, canbe prepared using various phage display methods known in the art. Inphage display methods, functional antibody domains are displayed on thesurface of a phage particle which carries polynucleotide sequencesencoding them. Phage with a desired binding property is selected from arepertoire or combinatorial antibody library (e.g., human or murine) byselecting directly with an antigen, typically an antigen bound orcaptured to a solid surface or bead. Phage used in these methods aretypically filamentous phage including fd and M13 with Fab, F_(v) ordisulfide stabilized F_(v) antibody domains are recombinantly fused toeither the phage gene III or gene VIII protein. In addition, methods canbe adapted for the construction of Fab expression libraries (see, e.g.,Huse, W. D. et al. (1989) Science 246:1275-1281) to allow rapid andeffective identification of monoclonal Fab fragments with the desiredspecificity for a HLA-DR polypeptide, e.g., a polypeptide orderivatives, fragments, analogs or homologs thereof. Other examples ofphage display methods that can be used to make the isolated antibodiesof the present disclosure include those disclosed in Huston, J. S. etal. (1988) Proc. Natl. Acad. Sci. U.S.A. 85:5879-5883; Chaudhary, V. K.et al. (1990) Proc. Natl. Acad. Sci. U.S.A., 87:1066-1070; Brinkman etal., J. Immunol. Methods 182: 41-50 (1995); Ames, R. S. et al. (1995) J.Immunol. Methods 184:177-186; Kettleborough et al., Eur. J. Immunol. 24:952-958 (1994); Persic, L. et al. (1997) Gene 187:9-18; Burton, D. R. etal. (1994) Advances in Immunology 57:191-280; International PatentApplication No. PCT/GB91/01134; International Patent ApplicationPublication Nos. WO 90/02809; WO 91/10737; WO 92/01047; WO 92/18619; WO93/11236; WO 95/15982; WO 95/20401; WO 96/06213; WO 92/01047 (MedicalResearch Council et al.); WO 97/08320 (Morphosys); WO 92/01047(CAT/MRC); WO 91/17271 (Affymax); and U.S. Pat. Nos. 5,698,426;5,223,409; 5,403,484; 5,580,717; 5,427,908; 5,750,753; 5,821,047;5,571,698; 5,427,908; 5,516,637; 5,780,225; 5,658,727 and 5,733,743.

Methods useful for displaying polypeptides on the surface ofbacteriophage particles by attaching the polypeptides via disulfidebonds have been described by Lohning, U.S. Pat. No. 6,753,136. Asdescribed in the above references, after phage selection, the antibodycoding regions from the phage can be isolated and used to generate wholeantibodies, including human antibodies, or any other desired antigenbinding fragment, and expressed in any desired host including mammaliancells, insect cells, plant cells, yeast, and bacteria. For example,techniques to recombinantly produce Fab, Fab′ and F(ab′)₂ fragments canalso be employed using methods known in the art such as those disclosedin International Patent Application Publication No. WO 92/22324;Mullinax, R. L. et al. (1992) BioTechniques 12:864-869; Sawai, H. et al.(1995) AJRI 34:26-34; and Better, M. et al. (1988) Science240:1041-1043.

Generally, hybrid antibodies or hybrid antibody fragments that arecloned into a display vector can be selected against the appropriateantigen in order to identify variants that maintained good bindingactivity, because the antibody or antibody fragment will be present onthe surface of the phage or phagemid particle. See e.g., Barbas III etal., Phage Display, A Laboratory Manual (Cold Spring Harbor LaboratoryPress, Cold Spring Harbor, N.Y., 2001). However, other vector formatscould be used for this process, such as cloning the antibody fragmentlibrary into a lytic phage vector (modified T7 or Lambda Zap systems)for selection and/or screening.

Alternate Methods of Antibody Production. Antibodies may also beproduced by inducing in vivo production in the lymphocyte population orby screening recombinant immunoglobulin libraries or panels of highlyspecific binding reagents (Orlandi, R. et al. (1989) Proc. Natl. Acad.Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299).

Alternatively, techniques for the production of single chain antibodiesmay be used. Single chain antibodies (scF_(v)s) comprise a heavy chainvariable region and a light chain variable region connected with alinker peptide (typically around 5 to 25 amino acids in length). In thescF_(v), the variable regions of the heavy chain and the light chain maybe derived from the same antibody or different antibodies. scF_(v)s maybe synthesized using recombinant techniques, for example by expressionof a vector encoding the scF_(v) in a host organism such as E. coli. DNAencoding scF_(v) can be obtained by performing amplification using apartial DNA encoding the entire or a desired amino acid sequence of aDNA selected from a DNA encoding the heavy chain or the variable regionof the heavy chain of the above-mentioned antibody and a DNA encodingthe light chain or the variable region of the light chain thereof as atemplate, by PCR using a primer pair that defines both ends thereof, andfurther performing amplification combining a DNA encoding a polypeptidelinker portion and a primer pair that defines both ends thereof, so asto ligate both ends of the linker to the heavy chain and the lightchain, respectively. An expression vector containing the DNA encodingscF_(v) and a host transformed by the expression vector can be obtainedaccording to conventional methods known in the art.

Antigen binding fragments may also be generated, for example the F(ab′)₂fragments which can be produced by pepsin digestion of the antibodymolecule and the Fab fragments which can be generated by reducing thedisulfide bridges of the F(ab′)₂ fragments. Alternatively, Fabexpression libraries may be constructed to allow rapid and easyidentification of monoclonal Fab fragments with the desired specificity(Huse, W. D. et al. (1989) Science 256:1275-1281).

Antibody Modifications. The antibodies of the present disclosure may bemultimerized to increase the affinity for an antigen. The antibody to bemultimerized may be one type of antibody or a plurality of antibodieswhich recognize a plurality of epitopes of the same antigen. As a methodof multimerization of the antibody, binding of the IgG CH3 domain to twoscF_(v) molecules, binding to streptavidin, introduction of ahelix-turn-helix motif and the like can be exemplified.

The antibody compositions disclosed herein may be in the form of aconjugate formed between any of these antibodies and another agent(immunoconjugate). In one aspect, the antibodies disclosed herein areconjugated to radioactive material. In another aspect, the antibodiesdisclosed herein can be bound to various types of molecules such aspolyethylene glycol (PEG).

Antibody Screening. Various immunoassays may be used for screening toidentify antibodies having the desired specificity. Numerous protocolsfor competitive binding or immunoradiometric assays using eitherpolyclonal or monoclonal antibodies with established specificities arewell known in the art. Such immunoassays typically involve themeasurement of complex formation between HLA-DR, or any fragment oroligopeptide thereof and its specific antibody. A two-site,monoclonal-based immunoassay utilizing monoclonal antibodies specific totwo non-interfering HLA-DR epitopes may be used, but a competitivebinding assay may also be employed (Maddox, D. E. et al. (1983) J. Exp.Med. 158:1211-1216).

Antibody Purification. The antibodies disclosed herein can be purifiedto homogeneity. The separation and purification of the antibodies can beperformed by employing conventional protein separation and purificationmethods.

By way of example only, the antibody can be separated and purified byappropriately selecting and combining use of chromatography columns,filters, ultrafiltration, salt precipitation, dialysis, preparativepolyacrylamide gel electrophoresis, isoelectric focusingelectrophoresis, and the like. Strategies for Protein Purification andCharacterization: A Laboratory Course Manual, Marshak, D. R. et al.eds., Cold Spring Harbor Laboratory Press (1996); Antibodies: ALaboratory Manual. Ed Harlow and David Lane, Cold Spring HarborLaboratory (1988).

Examples of chromatography include affinity chromatography, ion exchangechromatography, hydrophobic chromatography, gel filtrationchromatography, reverse phase chromatography, and adsorptionchromatography. In one aspect, chromatography can be performed byemploying liquid chromatography such as HPLC or FPLC.

In one aspect, a Protein A column or a Protein G column may be used inaffinity chromatography. Other exemplary columns include a Protein Acolumn, Hyper D, POROS, Sepharose F. F. (Pharmacia) and the like.

Methods of Use

General. The antibodies disclosed herein are useful in methods known inthe art relating to the localization and/or quantitation of a HLA-DRpolypeptide (e.g., for use in measuring levels of the HLA-DR polypeptidewithin appropriate physiological samples, for use in diagnostic methods,for use in imaging the polypeptide, and the like). The antibodiesdisclosed herein are useful in isolating a HLA-DR polypeptide bystandard techniques, such as affinity chromatography orimmunoprecipitation. A HLA-DR antibody disclosed herein can facilitatethe purification of natural HLA-DR polypeptides from biological samples,e.g., mammalian sera or cells as well as recombinantly-produced HLA-DRpolypeptides expressed in a host system. Moreover, HLA-DR antibody canbe used to detect a HLA-DR polypeptide (e.g., in plasma, a cellularlysate or cell supernatant) in order to evaluate the abundance andpattern of expression of the polypeptide. The HLA-DR antibodiesdisclosed herein can be used diagnostically to monitor HLA-DR levels intissue as part of a clinical testing procedure, e.g., to determine theefficacy of a given treatment regimen. The detection can be facilitatedby coupling (i.e., physically linking) the HLA-DR antibodies disclosedherein to a detectable substance.

In another aspect, provided herein is a composition comprising anantibody or antigen binding fragment as disclosed herein bound to apeptide comprising, for example, a human HLA-DR protein or a fragmentthereof. In one aspect, the peptide is associated with a cell. Forexample, the composition may comprise a disaggregated cell samplelabeled with an antibody or antibody fragment as disclosed herein, whichcomposition is useful in, for example, affinity chromatography methodsfor isolating cells or for flow cytometry-based cellular analysis orcell sorting. As another example, the composition may comprise a fixedtissue sample or cell smear labeled with an antibody or antibodyfragment as disclosed herein, which composition is useful in, forexample, immunohistochemistry or cytology analysis. In another aspect,the antibody or the antibody fragment is bound to a solid support, whichis useful in, for example: ELISAs; affinity chromatography orimmunoprecipitation methods for isolating HLA-DR proteins or fragmentsthereof, HLA-DR-positive cells, or complexes containing HLA-DR and othercellular components. In another aspect, the peptide is bound to a solidsupport. For example, the peptide may be bound to the solid support viaa secondary antibody specific for the peptide, which is useful in, forexample, sandwich ELISAs. As another example, the peptide may be boundto a chromatography column, which is useful in, for example, isolationor purification of antibodies according to the present technology. Inanother aspect, the peptide is disposed in a solution, such as a lysissolution or a solution containing a sub-cellular fraction of afractionated cell, which is useful in, for example, ELISAs and affinitychromatography or immunoprecipitation methods of isolating HLA-DRproteins or fragments thereof or complexes containing HLA-DR and othercellular components. In another aspect, the peptide is associated with amatrix, such as, for example, a gel electrophoresis gel or a matrixcommonly used for western blotting (such as membranes made ofnitrocellulose or polyvinylidene difluoride), which compositions areuseful for electrophoretic and/or immunoblotting techniques, such asWestern blotting.

Detection of HLA-DR Polypeptide. An exemplary method for detecting thelevel of HLA-DR polypeptides in a biological sample involves obtaining abiological sample from a subject and contacting the biological samplewith a HLA-DR binding agent, e.g., an antibody disclosed herein or knownin the art that is capable of detecting the HLA-DR polypeptides.

In one aspect, the HLA-DR antibodies Lym-1, or Lym-2, or fragmentsthereof are detectably labeled. The term “labeled”, with regard to theantibody is intended to encompass direct labeling of the antibody bycoupling (i.e., physically linking) a detectable substance to theantibody, as well as indirect labeling of the antibody by reactivitywith another compound that is directly labeled. Non-limiting examples ofindirect labeling include detection of a primary antibody using afluorescently-labeled secondary antibody and end-labeling of a DNA probewith biotin such that it can be detected with fluorescently-labeledstreptavidin.

The detection method of the present disclosure can be used to detectexpression levels of HLA-DR polypeptides in a biological sample in vitroas well as in vivo. In vitro techniques for detection of HLA-DRpolypeptides include enzyme linked immunosorbent assays (ELISAs),Western blots, flow cytometry, immunoprecipitations, radioimmunoassay,and immunofluorescence (e.g., IHC). Furthermore, in vivo techniques fordetection of HLA-DR polypeptides include introducing into a subject alabeled anti-HLA-DR antibody. By way of example only, the antibody canbe labeled with a detectable marker, e.g. a radioactive marker whosepresence and location in a subject can be detected by standard imagingtechniques. In one aspect, the biological sample contains polypeptidemolecules from the subject.

Immunoassay and Imaging. A HLA-DR antibody disclosed herein can be usedto assay HLA-DR polypeptide levels in a biological sample (e.g., humanplasma) using antibody-based techniques. For example, protein expressionin tissues can be studied with classical immunohistochemical (IHC)staining methods. Jalkanen, M. et al. (1985) J. Cell. Biol. 101:976-985;Jalkanen, M. et al. (1987) J. Cell. Biol. 105:3087-3096. Otherantibody-based methods useful for detecting protein gene expressioninclude immunoassays, such as the enzyme linked immunosorbent assay(ELISA) and the radioimmunoassay (MA). Suitable antibody assay labelsare known in the art and include enzyme labels, such as, glucoseoxidase, and radioisotopes or other radioactive agents, such as iodine(¹²⁵I, ¹²¹I, ¹³¹I), carbon (¹⁴C), sulfur (³⁵S), tritium (³H), indium(¹¹²In), and technetium (⁹⁹mTc), and fluorescent labels, such asfluorescein and rhodamine, and biotin.

In addition to assaying HLA-DR polypeptide levels in a biologicalsample, HLA-DR polypeptide levels can also be detected in vivo byimaging. Labels that can be incorporated with anti-HLA-DR antibodies forin vivo imaging of HLA-DR polypeptide levels include those detectable byX-radiography, NMR or ESR. For X-radiography, suitable labels includeradioisotopes such as barium or cesium, which emit detectable radiationbut are not overtly harmful to the subject. Suitable markers for NMR andESR include those with a detectable characteristic spin, such asdeuterium, which can be incorporated into the HLA-DR antibody bylabeling of nutrients for the relevant scF_(v) clone.

A HLA-DR antibody which has been labeled with an appropriate detectableimaging moiety, such as a radioisotope (e.g., ¹³¹I, ¹¹²In, ¹⁹⁹mTc), aradio-opaque substance, or a material detectable by nuclear magneticresonance, is introduced (e.g., parenterally, subcutaneously, orintraperitoneally) into the subject. It will be understood in the artthat the size of the subject and the imaging system used will determinethe quantity of imaging moiety needed to produce diagnostic images. Inthe case of a radioisotope moiety, for a human subject, the quantity ofradioactivity injected will normally range from about 5 to 20millicuries of ⁹⁹mTc. The labeled HLA-DR antibody will thenpreferentially accumulate at the location of cells which contain thespecific target polypeptide. For example, in vivo tumor imaging isdescribed in Burchiel, S. W. et al. (1982) Tumor Imaging: TheRadiochemical Detection of Cancer 13.

In some aspects, HLA-DR antibodies containing structural modificationsthat facilitate rapid binding and cell uptake and/or slow release areuseful in in vivo imaging detection methods. In some aspects, the HLA-DRantibody contains a deletion in the CH2 constant heavy chain region ofthe antibody to facilitate rapid binding and cell uptake and/or slowrelease. In some aspects, a Fab fragment is used to facilitate rapidbinding and cell uptake and/or slow release. In some aspects, a F(ab)′2fragment is used to facilitate rapid binding and cell uptake and/or slowrelease.

Diagnostic Uses of HLA-DR antibodies. The HLA-DR antibody compositionsdisclosed herein are useful in diagnostic and prognostic methods. Assuch, the present disclosure provides methods for using the antibodiesdisclosed herein in the diagnosis of HLA-DR-related medical conditionsin a subject. Antibodies disclosed herein may be selected such that theyhave a high level of epitope binding specificity and high bindingaffinity to the HLA-DR polypeptide. In general, the higher the bindingaffinity of an antibody, the more stringent wash conditions can beperformed in an immunoassay to remove nonspecifically bound materialwithout removing the target polypeptide. Accordingly, HLA-DR antibodiesof the present technology useful in diagnostic assays usually havebinding affinities of at least 10⁻⁶, 10⁻⁷, 10⁻⁸, 10⁻⁹, 10⁻¹⁰, 10⁻¹¹, or10⁻¹² M. In certain aspects, HLA-DR antibodies used as diagnosticreagents have a sufficient kinetic on-rate to reach equilibrium understandard conditions in at least 12 hours, at least 5 hours, at least 1hour, or at least 30 minutes.

Some methods of the present technology employ polyclonal preparations ofanti-HLA-DR antibodies and polyclonal anti-HLA-DR antibody compositionsas diagnostic reagents, and other methods employ monoclonal isolates. Inmethods employing polyclonal human anti-HLA-DR antibodies prepared inaccordance with the methods described above, the preparation typicallycontains an assortment of HLA-DR antibodies, e.g., antibodies, withdifferent epitope specificities to the target polypeptide. Themonoclonal anti-HLA-DR antibodies of the present disclosure are usefulfor detecting a single antigen in the presence or potential presence ofclosely related antigens.

The HLA-DR antibodies of the present disclosure can be used asdiagnostic reagents for any kind of biological sample. In one aspect,the HLA-DR antibodies disclosed herein are useful as diagnostic reagentsfor human biological samples. HLA-DR antibodies can be used to detectHLA-DR polypeptides in a variety of standard assay formats. Such formatsinclude immunoprecipitation, Western blotting, ELISA, radioimmunoassay,flow cytometry, IHC and immunometric assays. See Harlow & Lane,Antibodies, A Laboratory Manual (Cold Spring Harbor Publications, NewYork, 1988); U.S. Pat. Nos. 3,791,932; 3,839,153; 3,850,752; 3,879,262;4,034,074, 3,791,932; 3,817,837; 3,839,153; 3,850,752; 3,850,578;3,853,987; 3,867,517; 3,879,262; 3,901,654; 3,935,074; 3,984,533;3,996,345; 4,034,074 and 4,098,876. Biological samples can be obtainedfrom any tissue (including biopsies), cell or body fluid of a subject.

In another aspect, the present disclosure provides methods fordetermining whether a subject can be effectively treated with CAR T cellor CAR NK cell composition as described herein. The method comprisesassaying a cancer or tumor sample isolated from the patient for HLA-DRprotein or polypeptide expression using any appropriate method, e.g.,immunohistochemistry using an HLA-DR antibody or the polymerase chainreaction (PCR). In one aspect, the expression level of the HLA-DRpolypeptide in the biological sample obtained from the subject isdetermined and compared with HLA-DR expression levels found in abiological sample obtained from a subject or a population of patientsfree of the disease. Increased expression of the HLA-DR polypeptide, ascompared to the expression level of the polypeptide or protein in thepatient sample(s) from the patients free of disease indicates that thepatient is likely to be responsive to the CAR T cell or CAR NK celltherapy of this disclosure, and lack of elevated expression indicatesthat the patient is not likely to be responsive to the CAR T cell or CARNK cell therapy. Non-limiting examples of samples include, e.g., anybody fluid including, but not limited to, e.g., sputum, serum, plasma,lymph, cystic fluid, urine, stool, cerebrospinal fluid, ascite fluid orblood and including biopsy samples of body tissue. The samples are alsoa tumor cell. The test sample used in the above-described method willvary based on the assay format, nature of the detection method and thetissues, cells or extracts used as the sample to be assayed. In afurther aspect, an effective amount of the HLA-DR CAR therapy isadministered to the subject or patient

In a particular aspect, the present disclosure relates to methods fordetermining if a patient is likely to respond or is not likely to HLA-DRCAR therapy. In specific embodiments, this method comprises contacting atumor sample isolated from the patient with an effective amount of anHLA-DR binding agent, e.g., an HLA-DR antibody and detecting thepresence of any agent or antibody bound to the tumor sample. In furtherembodiments, the presence of agent or antibody bound to the tumor sampleindicates that the patient is likely to respond to the HLA-DR CARtherapy and the absence of antibody bound to the tumor sample indicatesthat the patient is not likely to respond to the HLA-DR therapy.Non-limiting examples of samples include, e.g., any body fluidincluding, but not limited to, e.g., sputum, serum, plasma, lymph,cystic fluid, urine, stool, cerebrospinal fluid, ascite fluid or bloodand including biopsy samples of body tissue. The samples are also atumor cell. The test sample used in the above-described method will varybased on the assay format, nature of the detection method and thetissues, cells or extracts used as the sample to be assayed. In someembodiments, the method comprises the additional step of administeringan effective amount of the HLA-DR CAR therapy to a patient that isdetermined likely to respond to the HLA-DR CAR therapy. In someembodiments, the patient a HLA-DR expressing tumor and/or cancer.

There are a number of disease states in which the elevated expressionlevel of HLA-DR polypeptides is known to be indicative of whether asubject with the disease is likely to respond to a particular type oftherapy or treatment. Non-limiting examples of such disease statesinclude cancer, e.g., a carcinoma, a sarcoma or a leukemia. Thus, themethod of detecting a HLA-DR polypeptide in a biological sample can beused as a method of prognosis, e.g., to evaluate the likelihood that thesubject will respond to the therapy or treatment. The level of theHLA-DR polypeptide in a suitable tissue or body fluid sample from thesubject is determined and compared with a suitable control, e.g., thelevel in subjects with the same disease but who have responded favorablyto the treatment. Non-limiting examples of samples include, e.g., anybody fluid including, but not limited to, e.g., sputum, serum, plasma,lymph, cystic fluid, urine, stool, cerebrospinal fluid, ascite fluid orblood and including biopsy samples of body tissue. The samples are alsoa tumor cell. The test sample used in the above-described method willvary based on the assay format, nature of the detection method and thetissues, cells or extracts used as the sample to be assayed. Methods forpreparing protein extracts or membrane extracts of cells are known inthe art and can be readily adapted in order to obtain a sample which iscompatible with the system utilized.

In one aspect, the present disclosure provides for methods of monitoringthe influence of agents (e.g., the CART cell or CAR NK cell compositionsof this disclosure, drugs, compounds, or small molecules) on theexpression of HLA-DR polypeptides. Such assays can be applied in basicdrug screening and in clinical trials. For example, the effectiveness ofan agent to decrease HLA-DR polypeptide levels can be monitored inclinical trials of subjects exhibiting elevated expression of HLA-DR,e.g., patients diagnosed with cancer. An agent that affects theexpression of HLA-DR polypeptides can be identified by administering theagent and observing a response. In this way, the expression pattern ofthe HLA-DR polypeptide can serve as a marker, indicative of thephysiological response of the subject to the agent. Accordingly, thisresponse state may be determined before, and at various points during,treatment of the subject with the agent. In some embodiments, the methodfurther comprises the additional step of administering an effectiveamount of the HLA-DR CAR therapy to a patient that is determined torequire additional therapy.

Further method aspects of the present disclosure relate to methods fordetermining if a patient is likely to respond or is not likely to HLA-DRCAR therapy. In specific embodiments, this method comprises contacting atumor sample isolated from the patient with an effective amount of anHLA-DR antibody and detecting the presence of any antibody bound to thetumor sample. In further embodiments, the presence of antibody bound tothe tumor sample indicates that the patient is likely to respond to theHLA-DR CAR therapy and the absence of antibody bound to the tumor sampleindicates that the patient is not likely to respond to the HLA-DRtherapy. In some embodiments, the method comprises the additional stepof administering an effective amount of the HLA-DR CAR therapy to apatient that is determined likely to respond to the HLA-DR CAR therapy.In some embodiments, the patient a HLA-DR expressing tumor and/orcancer.

III. Kits

As set forth herein, the present disclosure provides diagnostic methodsfor determining the expression level of HLA-DR. In one particularaspect, the present disclosure provides kits for performing thesemethods as well as instructions for carrying out the methods of thepresent disclosure such as collecting tissue and/or performing thescreen, and/or analyzing the results.

The kit comprises, or alternatively consists essentially of, or yetfurther consists of, a HLA-DR antibody composition (e.g., monoclonalantibodies) disclosed herein, and instructions for use. The kits areuseful for detecting the presence of HLA-DR polypeptides in a biologicalsample, e.g., any body fluid including, but not limited to, e.g.,sputum, serum, plasma, lymph, cystic fluid, urine, stool, cerebrospinalfluid, acitic fluid or blood and including biopsy samples of bodytissue. The test samples may also be a tumor cell, a normal celladjacent to a tumor, a normal cell corresponding to the tumor tissuetype, a blood cell, a peripheral blood lymphocyte, or combinationsthereof. The test sample used in the above-described method will varybased on the assay format, nature of the detection method and thetissues, cells or extracts used as the sample to be assayed. Methods forpreparing protein extracts or membrane extracts of cells are known inthe art and can be readily adapted in order to obtain a sample which iscompatible with the system utilized.

In some aspects, the kit can comprise: one or more HLA-DR antibodiescapable of binding and that bind a HLA-DR polypeptide in a biologicalsample (e.g., an antibody or antigen-binding fragment thereof having thesame antigen-binding specificity of HLA-DR antibody Lym-1 or Lym-2);means for determining the amount of the HLA-DR polypeptide in thesample; and means for comparing the amount of the HLA-DR polypeptide inthe sample with a standard. One or more of the HLA-DR antibodies may belabeled. The kit components, (e.g., reagents) can be packaged in asuitable container. The kit can further comprise instructions for usingthe kit to detect the HLA-DR polypeptides. In certain aspects, the kitcomprises a first antibody, e.g., attached to a solid support, whichbinds to a HLA-DR polypeptide; and, optionally; 2) a second, differentantibody which binds to either the HLA-DR polypeptide or the firstantibody and is conjugated to a detectable label.

The kit can also comprise, e.g., a buffering agent, a preservative or aprotein-stabilizing agent. The kit can further comprise componentsnecessary for detecting the detectable-label, e.g., an enzyme or asubstrate. The kit can also contain a control sample or a series ofcontrol samples, which can be assayed and compared to the test sample.Each component of the kit can be enclosed within an individual containerand all of the various containers can be within a single package, alongwith instructions for interpreting the results of the assays performedusing the kit. The kits of the present disclosure may contain a writtenproduct on or in the kit container. The written product describes how touse the reagents contained in the kit.

As amenable, these suggested kit components may be packaged in a mannercustomary for use by those of skill in the art. For example, thesesuggested kit components may be provided in solution or as a liquiddispersion or the like.

IV. Carriers

The antibodies also can be bound to many different carriers. Thus, thisdisclosure also provides compositions containing the antibodies andanother substance, active or inert. Examples of well-known carriersinclude glass, polystyrene, polypropylene, polyethylene, dextran, nylon,amylases, natural and modified celluloses, polyacrylamides, agaroses andmagnetite. The nature of the carrier can be either soluble or insolublefor purposes of the disclosure. Those skilled in the art will know ofother suitable carriers for binding antibodies, or will be able toascertain such, using routine experimentation.

Chimeric Antigen Receptors and Uses Thereof

I. Compositions

The present disclosure provides chimeric antigen receptors (CAR) thatbind to HLA-DR comprising, or consisting essentially of, a cellactivation moiety comprising an extracellular, transmembrane, andintracellular domain. The extracellular domain comprises atarget-specific binding element otherwise referred to as the antigenbinding domain. The intracellular domain or cytoplasmic domaincomprises, a costimulatory signaling region and a zeta chain portion.The CAR may optionally further comprise a spacer domain of up to 300amino acids, preferably 10 to 100 amino acids, more preferably 25 to 50amino acids.

Antigen Binding Domain. In certain aspects, the present disclosureprovides a CAR that comprises, or alternatively consists essentiallythereof, or yet consists of an antigen binding domain specific toHLA-DR. In some embodiments, the antigen binding domain comprises, oralternatively consists essentially thereof, or yet consists of theantigen binding domain of an anti-HLA-DR antibody. In furtherembodiments, the heavy chain variable region and light chain variableregion of an anti-HLA-DR antibody comprises, or alternatively consistsessentially thereof, or yet consists of the antigen binding domain theanti-HLA-DR antibody.

In some embodiments, the heavy chain variable region of the antibodycomprises, or consists essentially thereof, or consists of SEQ ID NOs: 7to 10 or an equivalent of each thereof and/or comprises one or more CDRregions comprising SEQ ID NOs: 1 to 6 or an equivalent of each thereof.In some embodiments, the light chain variable region of the antibodycomprises, or consists essentially thereof, or consists of SEQ ID NOs:17 to 20 or an equivalent thereof and/or comprises one or more CDRregions comprising SEQ ID NOs: 11 to 16 or an equivalent thereof.

Transmembrane Domain. The transmembrane domain may be derived eitherfrom a natural or from a synthetic source. Where the source is natural,the domain may be derived from any membrane-bound or transmembraneprotein. Transmembrane regions of particular use in this disclosure maybe derived from CD8, CD28, CD3, CD45, CD4, CDS, CDS, CD9, CD 16, CD22,CD33, CD37, CD64, CD80, CD86, CD 134, CD137, CD 154, TCR. Alternativelythe transmembrane domain may be synthetic, in which case it willcomprise predominantly hydrophobic residues such as leucine and valine.Preferably a triplet of phenylalanine, tryptophan and valine will befound at each end of a synthetic transmembrane domain. Optionally, ashort oligo- or polypeptide linker, preferably between 2 and 10 aminoacids in length may form the linkage between the transmembrane domainand the cytoplasmic signaling domain of the CAR. A glycine-serinedoublet provides a particularly suitable linker.

Cytoplasmic Domain. The cytoplasmic domain or intracellular signalingdomain of the CAR is responsible for activation of at least one of thetraditional effector functions of an immune cell in which a CAR has beenplaced. The intracellular signaling domain refers to a portion of aprotein which transduces the effector function signal and directs theimmune cell to perform its specific function. An entire signaling domainor a truncated portion thereof may be used so long as the truncatedportion is sufficient to transduce the effector function signal.Cytoplasmic sequences of the TCR and co-receptors as well as derivativesor variants thereof can function as intracellular signaling domains foruse in a CAR. Intracellular signaling domains of particular use in thisdisclosure may be derived from FcR, TCR, CD3, CDS, CD22, CD79a, CD79b,CD66d. Since signals generated through the TCR are alone insufficientfor full activation of a T cell, a secondary or co-stimulatory signalmay also be required. Thus, the intracellular region of a co-stimulatorysignaling molecule, including but not limited CD27, CD28, 4-IBB (CD137), OX40, CD30, CD40, PD-1, ICOS, lymphocyte function-associatedantigen-1 (LFA-1), CD2, CD7, LIGHT, NKG2C, B7-H3, or a ligand thatspecifically binds with CD83, to may also be included in the cytoplasmicdomain of the CAR.

In some embodiments, the cell activation moiety of the chimeric antigenreceptor is a T-cell signaling domain comprising, or alternativelyconsisting essentially of, or yet further consisting of, one or moreproteins or fragments thereof selected from the group consisting of CD8protein, CD28 protein, 4-1BB protein, and CD3-zeta protein.

In specific embodiments, the CAR comprises, or alternatively consistsessentially thereof, or yet consists of an antigen binding domain of ananti-HLA-DR antibody, a CD8 α hinge domain, a CD8 α transmembranedomain, a costimulatory signaling region, and a CD3 zeta signalingdomain. In further embodiments, the costimulatory signaling regioncomprises either or both a CD28 costimulatory signaling region and a4-1BB costimulatory signaling region.

In some embodiments, the CAR can further comprise a detectable marker orpurification marker.

In a further aspect, this disclosure provides complex comprising anHLA-DR CAR cell bound to its target cell. In a further aspect, thecomplex is detectably labeled. Detectable labels are known in the artand briefly described herein.

II. Process for Preparing CARs

Aspects of the present disclosure relate to an isolated cell comprisinga HLA-DR CAR and methods of producing such cells. The cell is aprokaryotic or a eukaryotic cell. In one aspect, the cell is a T cell ora NK cell. The eukaryotic cell can be from any preferred species, e.g.,an animal cell, a mammalian cell such as a human, a feline or a caninecell.

In specific embodiments, the isolated cell comprises, or alternativelyconsists essentially of, or yet further consists of an exogenous CARcomprising, or alternatively consisting essentially of, or yet furtherconsisting of, an antigen binding domain of an anti-HLA-DR antibody, aCD8 α hinge domain, a CD8 α transmembrane domain, a CD28 costimulatorysignaling region and/or a 4-1BB costimulatory signaling region, and aCD3 zeta signaling domain. In certain embodiments, the isolated cell isa T-cell, e.g., an animal T-cell, a mammalian T-cell, a feline T-cell, acanine T-cell or a human T-cell. In certain embodiments, the isolatedcell is an NK-cell, e.g., an animal NK-cell, a mammalian NK-cell, afeline NK-cell, a canine NK-cell or a human NK-cell.

In certain embodiments, methods of producing HLA-DR CAR expressing cellsare disclosed comprising, or alternatively consisting essentially of:(i) transducing a population of isolated cells with a nucleic acidsequence encoding a HLA-DR CAR and (ii) selecting a subpopulation ofcells that have been successfully transduced with said nucleic acidsequence of step (i). In some embodiments, the isolated cells areT-cells, an animal T-cell, a mammalian T-cell, a feline T-cell, a canineT-cell or a human T-cell, thereby producing HLA-DR CAR T-cells. Incertain embodiments, the isolated cell is an NK-cell, e.g., an animalNK-cell, a mammalian NK-cell, a feline NK-cell, a canine NK-cell or ahuman NK-cell, thereby producing HLA-DR CAR NK-cells.

Sources of Isolated Cells. Prior to expansion and genetic modificationof the cells disclosed herein, cells may be obtained from a subject—forinstance, in embodiments involving autologous therapy—or a commerciallyavailable culture.

Cells can be obtained from a number of sources in a subject, includingperipheral blood mononuclear cells, bone marrow, lymph node tissue, cordblood, thymus tissue, tissue from a site of infection, ascites, pleuraleffusion, spleen tissue, and tumors.

Methods of isolating relevant cells are well known in the art and can bereadily adapted to the present application; an exemplary method isdescribed in the examples below. Isolation methods for use in relationto this disclosure include, but are not limited to Life TechnologiesDynabeads® system; STEMcell Technologies EasySep™, RoboSep™,RosetteSep™, SepMate™; Miltenyi Biotec MACS™ cell separation kits, andother commercially available cell separation and isolation kits.Particular subpopulations of immune cells may be isolated through theuse of beads or other binding agents available in such kits specific tounique cell surface markers. For example, MACS™ CD4+ and CD8+ MicroBeadsmay be used to isolate CD4+ and CD8+ T-cells

Alternatively, cells may be obtained through commercially available cellcultures, including but not limited to, for T-cells, lines BCL2 (AAA)Jurkat (ATCC® CRL-2902™) BCL2 (S70A) Jurkat (ATCC® CRL-2900™), BCL2(S87A) Jurkat (ATCC® CRL-2901™), BCL2 Jurkat (ATCC® CRL-2899™), NeoJurkat (ATCC® CRL-2898™); for NK cells, lines NK-92 (ATCC® CRL-2407™),NK-92MI (ATCC® CRL-2408™).

Vectors. CARs may be prepared using vectors. Aspects of the presentdisclosure relate to an isolated nucleic acid sequence encoding a HLA-DRCAR and vectors comprising, or alternatively consisting essentially of,or yet further consisting of, an isolated nucleic acid sequence encodingthe CAR and its complement and equivalents of each thereof.

In some embodiments, the isolated nucleic acid sequence encodes for aCAR comprising, or alternatively consisting essentially of, or yetfurther consisting of an antigen binding domain of an anti-HLA-DRantibody, a CD8 α hinge domain, a CD8 α transmembrane domain, a CD28costimulatory signaling region and/or a 4-1BB costimulatory signalingregion, and a CD3 zeta signaling domain. In specific embodiments, theisolated nucleic acid sequence comprises, or alternatively consistingessentially thereof, or yet further consisting of, sequences encoding(a) an antigen binding domain of an anti-HLA-DR antibody followed by (b)a CD8 α hinge domain, (c) a CD8 α transmembrane domain followed by (d) aCD28 costimulatory signaling region and/or a 4-1BB costimulatorysignaling region followed by (e) a CD3 zeta signaling domain.

In some embodiments, the isolated nucleic acid sequence comprises, oralternatively consists essentially thereof, or yet further consists of,a Kozak consensus sequence upstream of the sequence encoding the antigenbinding domain of the anti-HLA-DR antibody. In some embodiments, theisolated nucleic acid comprises a polynucleotide conferring antibioticresistance.

In some embodiments, the isolated nucleic acid sequence is comprised ina vector. In certain embodiments, the vector is a plasmid. In otherembodiments, the vector is a viral vector. In specific embodiments, thevector is a lentiviral vector.

The preparation of exemplary vectors and the generation of CARexpressing cells using said vectors is discussed in detail in theexamples below. In summary, the expression of natural or syntheticnucleic acids encoding CARs is typically achieved by operably linking anucleic acid encoding the CAR polypeptide or portions thereof to apromoter, and incorporating the construct into an expression vector. Thevectors can be suitable for replication and integration eukaryotes.Methods for producing cells comprising vectors and/or exogenous nucleicacids are well-known in the art. See, for example, Sambrook et al.(2001) Molecular Cloning: A Laboratory Manual, Cold Spring HarborLaboratory, New York).

In one aspect, the term “vector” intends a recombinant vector thatretains the ability to infect and transduce non-dividing and/orslowly-dividing cells and integrate into the target cell's genome. Inseveral aspects, the vector is derived from or based on a wild-typevirus. In further aspects, the vector is derived from or based on awild-type lentivirus. Examples of such, include without limitation,human immunodeficiency virus (HIV), equine infectious anemia virus(EIAV), simian immunodeficiency virus (SIV) and feline immunodeficiencyvirus (FIV). Alternatively, it is contemplated that other retrovirus canbe used as a basis for a vector backbone such murine leukemia virus(MLV). It will be evident that a viral vector according to thedisclosure need not be confined to the components of a particular virus.The viral vector may comprise components derived from two or moredifferent viruses, and may also comprise synthetic components. Vectorcomponents can be manipulated to obtain desired characteristics, such astarget cell specificity.

The recombinant vectors of this disclosure are derived from primates andnon-primates. Examples of primate lentiviruses include the humanimmunodeficiency virus (HIV), the causative agent of human acquiredimmunodeficiency syndrome (AIDS), and the simian immunodeficiency virus(SIV). The non-primate lentiviral group includes the prototype “slowvirus” visna/maedi virus (VMV), as well as the related caprinearthritis-encephalitis virus (CAEV), equine infectious anemia virus(EIAV) and the more recently described feline immunodeficiency virus(FIV) and bovine immunodeficiency virus (BIV). Prior art recombinantlentiviral vectors are known in the art, e.g., see U.S. Pat. Nos.6,924,123; 7,056,699; 7,07,993; 7,419,829 and 7,442,551, incorporatedherein by reference.

U.S. Pat. No. 6,924,123 discloses that certain retroviral sequencefacilitate integration into the target cell genome. This patent teachesthat each retroviral genome comprises genes called gag, pol and envwhich code for virion proteins and enzymes. These genes are flanked atboth ends by regions called long terminal repeats (LTRs). The LTRs areresponsible for proviral integration, and transcription. They also serveas enhancer-promoter sequences. In other words, the LTRs can control theexpression of the viral genes. Encapsidation of the retroviral RNAsoccurs by virtue of a psi sequence located at the 5′ end of the viralgenome. The LTRs themselves are identical sequences that can be dividedinto three elements, which are called U3, R and U5. U3 is derived fromthe sequence unique to the 3′ end of the RNA. R is derived from asequence repeated at both ends of the RNA, and U5 is derived from thesequence unique to the 5′end of the RNA. The sizes of the three elementscan vary considerably among different retroviruses. For the viralgenome. and the site of poly (A) addition (termination) is at theboundary between R and U5 in the right hand side LTR. U3 contains mostof the transcriptional control elements of the provirus, which includethe promoter and multiple enhancer sequences responsive to cellular andin some cases, viral transcriptional activator proteins.

With regard to the structural genes gag, pol and env themselves, gagencodes the internal structural protein of the virus. Gag protein isproteolytically processed into the mature proteins MA (matrix), CA(capsid) and NC (nucleocapsid). The pol gene encodes the reversetranscriptase (RT), which contains DNA polymerase, associated RNase Hand integrase (IN), which mediate replication of the genome.

For the production of viral vector particles, the vector RNA genome isexpressed from a DNA construct encoding it, in a host cell. Thecomponents of the particles not encoded by the vector genome areprovided in trans by additional nucleic acid sequences (the “packagingsystem”, which usually includes either or both of the gag/pol and envgenes) expressed in the host cell. The set of sequences required for theproduction of the viral vector particles may be introduced into the hostcell by transient transfection, or they may be integrated into the hostcell genome, or they may be provided in a mixture of ways. Thetechniques involved are known to those skilled in the art.

Retroviral vectors for use in this disclosure include, but are notlimited to Invitrogen's pLenti series versions 4, 6, and 6.2 “ViraPower”system. Manufactured by Lentigen Corp.; pHIV-7-GFP, lab generated andused by the City of Hope Research Institute; “Lenti-X” lentiviralvector, pLVX, manufactured by Clontech; pLKO.1-puro, manufactured bySigma-Aldrich; pLemiR, manufactured by Open Biosystems; and pLV, labgenerated and used by Charite Medical School, Institute of Virology(CBF), Berlin, Germany.

Regardless of the method used to introduce exogenous nucleic acids intoa host cell or otherwise expose a cell to the inhibitor of the presentdisclosure, in order to confirm the presence of the recombinant DNAsequence in the host cell, a variety of assays may be performed. Suchassays include, for example, “molecular biological” assays well known tothose of skill in the art, such as Southern and Northern blotting,RT-PCR and PCR; “biochemical” assays, such as detecting the presence orabsence of a particular peptide, e.g., by immunological means (ELISAsand Western blots) or by assays described herein to identify agentsfalling within the scope of the disclosure.

Activation and Expansion of Cells. Whether prior to or after geneticmodification of the cells to express a desirable CAR, the cells can beactivated and expanded using generally known methods such as thosedescribed in U.S. Pat. Nos. 6,352,694; 6,534,055; 6,905,680; 6,692,964;5,858,358; 6,887,466; 6,905,681; 7,144,575; 7,067,318; 7,172,869;7,232,566; 7,175,843; 5,883,223; 6,905,874; 6,797,514 and 6,867,041.Stimulation with the HLA-DR antigen ex vivo can activate and expand theselected CAR expressing cell subpopulation. Alternatively, the cells maybe activated in vivo by interaction with HLA-DR antigen.

Methods of activating relevant cells are well known in the art and canbe readily adapted to the present application; an exemplary method isdescribed in the examples below. Isolation methods for use in relationto this disclosure include, but are not limited to Life TechnologiesDynabeads® system activation and expansion kits; BD BiosciencesPhosflow™ activation kits, Miltenyi Biotec MACS™ activation/expansionkits, and other commercially available cell kits specific to activationmoieties of the relevant cell. Particular subpopulations of immune cellsmay be activated or expanded through the use of beads or other agentsavailable in such kits. For example, α-CD3/α-CD28 Dynabeads® may be usedto activate and expand a population of isolated T-cells

III. Methods of Use

Therapeutic Application. Method aspects of the present disclosure relateto methods for inhibiting the growth of a tumor in a subject in needthereof and/or for treating a cancer patient in need thereof. In someembodiments, the tumors/cancer is B-cell lymphoma or leukemiatumors/cancer. In some embodiments, the tumor is a solid tumor, e.g. acarcinoma. In some embodiments, the tumor or cancer expresses HLA-DR. Incertain embodiments, these methods comprise, or alternatively consistessentially of, or yet further consist of, administering to the subjector patient an effective amount of an isolated cell. In furtherembodiments, this isolated cell comprises a HLA-DR CAR. In still furtherembodiments, the isolated cell is a T cell or an NK cell. In someembodiments, the isolated cell is autologous to the subject or patientbeing treated. In a further aspect, the tumor expresses HLA-DR antigenand the subject has been selected for the therapy by a diagnostic, suchas the one described herein. The therapy can be a first line therapy, asecond line therapy, a third line therapy, or a fourth line therapy orany additional therapy as determined by the treating physician. They canbe combined with other therapies and administered sequentially orconcurrently.

The CAR cells as disclosed herein may be administered either alone or incombination with diluents, other anti-cancer therapeutics other than theCAR cell, and/or with other components such as cytokines or other cellpopulations that are immunostimulatory.

Pharmaceutical compositions disclosed herein may be administered in amanner appropriate to the disease to be treated or prevented. Thequantity and frequency of administration will be determined by suchfactors as the condition of the patient, and the type and severity ofthe patient's disease, although appropriate dosages may be determined byclinical trials.

IV. Carriers

Additional aspects of the disclosure relate to compositions comprising acarrier and one or more of the products—e.g., an isolated cellcomprising a HLA-DR CAR, an isolated nucleic acid, a vector, an isolatedcell of any anti-HLA-DR antibody or CAR cell, an anti-HLA-DR—describedin the embodiments disclosed herein.

Briefly, pharmaceutical compositions disclosed herein including but notlimited to any one of the claimed compositions may comprise a targetcell population as described herein, in combination with one or morepharmaceutically or physiologically acceptable carriers, diluents orexcipients. Such compositions may comprise buffers such as neutralbuffered saline, phosphate buffered saline and the like; carbohydratessuch as glucose, mannose, sucrose or dextrans, mannitol; proteins;polypeptides or amino acids such as glycine; antioxidants; chelatingagents such as EDTA or glutathione; adjuvants (e.g., aluminumhydroxide); and preservatives. Compositions of the present disclosuremay be formulated for oral, intravenous, topical, enteral, and/orparenteral administration. In certain embodiments, the compositions ofthe present disclosure are formulated for intravenous administration.

EXAMPLES

The following examples are illustrative of procedures which can be usedin various instances in carrying the disclosure into effect.

Example 1—Generation of Mouse Anti-Human HLA-DR Monoclonal AntibodiesAntigen

Raji African Burkitt's lymphoma cell nuclei were used as the antigen forproducing the Lym-1 antibody. CLL biopsy cell nuclei were used as theantigen for producing the Lym-2 antibody.

Immunization Procedures

Four week old female BALB/c mice purchased from Harlan Laboratories wereimmunized every two weeks ×4 with 10⁷ nuclei emulsified with CompleteFreund's Adjuvant (first and second immunization) or incomplete Freund'sAdjuvant (third and fourth immunization). Mice were injectedintradermally with a total of 10⁷ nuclei/adjuvant divided into threeseparate spots on the back of the mice per immunization. Ten days afterthe last immunization, blood samples were obtained and tittered by ELISAprocedures on antigen coated plates. Mice showing the highest titersthen received a fifth immunization boost intravenously without adjuvantin which 10⁶ nuclei were injected via the lateral tail vein in a 100 μlsolution of sterile Phosphate Buffered Saline.

Generation of Hybridomas

Four days later, these mice were sacrificed and the spleens removed forthe hybridoma procedure. After dispersing the splenocytes in a solutionof RPMI-1640 medium containing Pen/Strep antibiotics, the splenocyteswere fused with murine NSO cells using PEG (Hybri MAX, mol wt 1450, Cat.No: p7181, Sigma). HAT selection was then used to enable only fusedcells to grow. Supernatant from wells with growing hybridoma cells werethen screened initially by ELISA against antigen coated plates andsecondarily by flow cytometry on HLA-DR positive (Raji) and negativehuman tumor cell lines (CEM T-cell leukemia). Hybridomas showing apositive and high mean fluorescent index (MFI) were selected forsubcloning by limiting dilution methods. Subclones were then retested byflow cytometry, frozen in liquid nitrogen, and expanded in 2 L vesselsto before antibody was purified by tandon Protein A or G and ionexchange chromatography methods. Purified antibodies were then vialedand stored at −20° C. until used.

Flow Cytometry Procedures and Data

Screening methods using flow cytometry were performed on HLA-DR positive(Raji) and negative (CEM) cell lines using supernatant from hybridomasfound positive by ELISA to antigen coated plates. Those hybridomasproducing high mean fluorescent indexes (MFI) were then subcloned andrescreened for selective positivity to HLA-DR. As shown below in FIGS.1A-1F, Lym-1 and Lym-2 produced high MFI to the HLA-DR expressing Rajicell line with a different profile than B1 antibody. From these data,Lym-1 and Lym-2 were selected to generate CAR-T cells as describedbelow.

Immunohistochemistry with Selected Antibodies

Antibodies Lym-1 and Lym-2 were found to stain HLA-DR positive cells inthe germinal centers of human tonsil tissue using standardimmunohistochemical procedures and antigen retrieval methods as shown inFIGS. 2A-2B. Staining in thymus, spleen and bone marrow was restrictedto B-cell or dendritic cells expressing the HLA-DR antigen (Table 3).

TABLE 3 Reactivity of Lym-1 and Lym-2 with human normal lymphoid andhematopoietic tissues in frozen sections or cytospins Organ Lym-1 Lym-2Lymph node Germinal center +++^(a) ++ Mantle zone + +++ T-cell zones − −Interdigitating histiocytes ++ ++ Sinus histiocytes − − Endothelium − −Thymus Cortex − − Medulla ++ Dendritic cells − Spleen White pulp ++B-cell zones ++ B-cell zones Red pulp − − Bone marrow Myeloid − −Erythroid − − Megakaryocytes − − ^(a)Intensity of immunoperoxidasestaining from − to +++.

As shown in FIGS. 3A-3B, HLA-DR positivity was seen on the cell membraneof antigen positive tumors such as intermediate grade B-cell lymphomas.Finally, tissue sections from normal tissues and organs showedrestricted reactivity to lymphoid B-cells and macrophages of the skin(Table 4). The availability of a companion diagnostic antibody forHLA-DR using immunohistochemistry enables the identification of patientslikely to benefit from HLA-DR CAR T-cell therapy in upcoming clinicaltrials.

TABLE 4 Reactivity of Lym-1 and Lym-2 with normal non-lymphoid tissuesin frozen sections Reactivity Tissue Lym-1 Lym-2 Adrenal −^(a) − Brain −− Breast − − Cervix − − Colon + surface epithelium − Duodenum − − Heart− − Kidney − − Liver − − Lung − − Ovary − − Pancreas − − Salivary glands− − Skin + macrophages only − Skeletal muscle − − Smooth muscle − −Stomach − − Testis − − Thyroid − − ^(a)Intensity of immunoperoxidasestaining from − to +++.

Live Cell Radioimmunoassay

Using Lym-1 or Lym-2, a panel of human lymphoma and solid tumor celllines were screened for binding using a live cell radioimmunoassayprocedure. For this assay, suspension cultures and solid tumor celllines which were dislodged from their flasks with EDTA-trypsin werewashed twice in cold buffer consisting of PBS, bovine serum albumin (1mg/ml), and 0.02% sodium azide. Cells (5×10⁵) resuspended in 100 μl ofwash buffer were pipetted into microwells pretreated overnight with BSA(10 mg/ml) in PBS to prevent antibody binding to the wells. Lym-1 orLym-2 supernatant were then added (100 μl/well) for a 30 minuteincubation period with continuous shaking using a microshaker apparatusfor 96 well plates at room temperature. After 4 washes, 100,000 cpm of1-125 goat anti-mouse IgG was then added in 100 μl and incubated withthe cells for an additional 30 minute incubation with continuousshaking. After 4 final washes, the wells were counted in a gamma counterto determine antibody binding to each cell preparation. The results ofthese studies showed that for a large panel of human lymphoma andleukemia biopsies, reactivity of Lym-1 and Lym-2 was restricted totumors of B-cell but not T-cell origin (Table 5).

TABLE 5 Reactivity of Lym-1 and Lym-2 with human malignant lymphoma andleukemia biopsy specimens Diagnosis Lym-1^(a) Lym-2^(a) Lymphomas^(b)(frozen sections of lymph node biopsies^(c)) Well-differentiatedlymphocytic 1/3 3/3 Poorly differentiated lymphocytic, nodular 0/2 2/2Poorly differentiated lymphocytic, diffuse 1/3 3/3 Mixed lymphocytic andhistiocytic 8/9 7/9 Histiocytic (B-cell) 12/17 12/17 T-cell 0/2 0/2Leukemias (cytospins of peripheral blood^(d)) Chronic lymphocytic B-celltype  4/10  8/10 T-cell type 0/5 0/5 ^(a)Positive/total. ^(b)Rappaportclassification. ^(c)Immunoperoxidase technique. ^(d)Indirectimmunofluorescence.

Consistent with these results, Lym-1 and Lym-2 was found to bind to aselect number of human lymphoma and leukemia cell lines as shown inTable 6.

TABLE 6 Reactivity of Lym-1 and Lym-2 with human malignant lymphoma celllines by live cell radioimmunoassay Cell Line Lym-1 Lym-2 Burkitt'sLymphoma Raji ++++^(a) ++ EB3 − − DG-75 ++++ ++++ NK-9 ++ ++++ AL-1 − +Daudi + +++ NU-AmB-1 + ++ SU-AmB-1 − + SU-AmB-2 − − RAMOS − − Chevallier++++ B46M + + B35M ++++ ++++ DND-39 + − U-698-M + ++ HRIK + − Large CellLymphoma SU-DHL-1 − − SU-DHL-2 − − SU-DHL-4 ++++ SU-DHL-5 + ++ SU-DHL-6+++ +++ SU-DHL-7 + SU-DHL-8 + SU-DHL-9 + + SU-DHL-10 ++++ SU-DHL-16 − −NU-DHL-1 ++++ U-937 − − Undifferentiated lymphoma NU-DUL-1 − + ^(a)−,<2,000 cpm; +, 2,000-6,000 cpm; ++, 6,000-10,000 cpm; +++, 10,000-15000cpm; ++++, >15,000 cpm.

By contrast, Lym-1 and Lym-2 was not found to bind to 35 human solidtumor cell lines using live cell radioimmunoassay procedures describedabove (Table 7).

TABLE 7 Reactivity of Lym-1 and Lym-2 with 35 human solid tumor celllines by live cell radioimmunoassay Cell line Derivation Lym-1 Lym-2734B Breast carcinoma −^(a) − 578T Breast carcinoma − − C-399 Coloncarcinoma − − Hutu-80 Colon carcinoma − − HT-29 Colon carcinoma − − HeLaCervical carcinoma − − SW 733 Papillary carcinoma of bladder − − SW 780Transitional cell carcinoma − − of bladder SW 451 Squamous cellcarcinoma of − − esophagus − − SW 579 Squamous cell carcinoma of − −thyroid SW 156 Hypernephroma − − 60 Small cell carcinoma of lung − − 464Small cell carcinoma of lung − − NCI-H69 Small cell carcinoma of lung −− 125 Adenocarcinoma of lung − − A427 Adenocarcinoma of lung − − A549Adenocarcinoma of lung − − SW 1503 Mesothelioma − − BM 166 Neuroblastoma− − IMR-5 Neuroblastoma − − Y79 Retinoblastoma − − A172 Astrocytoma − −SW 608 Astrocytoma − − U118 MG Glioblastoma − − NU-04 Glioblastoma − −CaCl 74-36 Melanoma − − Colo 38 Melanoma − − SW 872 Liposarcoma − − HS919 Liposarcoma − − SW 1045 Synovial sarcoma − − SW 80 Rhabdomyoscarcoma− − SW 1353 Chondrosarcoma − − 4-998 Osteogenic sarcoma − − 4-906Osteogenic sarcoma − − SU-CCS-1 Clear cell sarcoma − − ^(a)−, <2,000cpm; +, 2,000-6,000 cpm; ++, 6,000-10,000 cpm; +++, 10,000-15000 cpm;++++, >15,000 cpm.

Binding Profiles of Lym-1 and Lym-2 Antibodies and Identification ofLym-1 Antigen

Binding profiles and Scatchard plot analyses of Lym-1 binding with Rajicells is shown in FIG. 4A. Likewise, Scatchard plot analyses of Lym-2binding with the ARH-77 myeloma cell line are shown in FIG. 4B. Thesedata demonstrated that both antibodies have 10⁸ M⁻¹ binding affinitiesto antigen positive tumor cell lines. As shown in Table 8, when comparedto normal peripheral blood B cells, there was a two to four-folddecrease in binding affinities compared to that seen with tumor cells.In addition, metabolic labeling of Raji cells with ³⁵S-methionine and¹⁴C-leucine showed the characteristic banding pattern seen for HLA-DR(FIGS. 5A-5B). As a control, the SC-1 anti-HLA-DR antibody was used inparallel and gave the same banding pattern with identical proteinmolecular weights by SDS-gel electrophoresis.

TABLE 6 Avidity constants of Lym-1 and Lym-2 using target tumor celllines (Raji, ARH-77) and tonsil lymphocytes Monoclonal antibody Tumorcell line Tonsil Lym-1 4.02 × 10⁸ M⁻¹ 0.88 × 10⁸ M⁻¹ Lym-2 2.33 × 10⁸M⁻¹ 1.23 × 10⁸ M⁻¹

Example 2—Generation of HLA-DR CAR T-Cells Construction and SynthesisSingle Chain HLA-DR Antibody Genes

The DNA sequences for 2 high binding anti-HLA-DR antibodies generated inthe laboratory (Lym-1 and Lym-2) are obtained from MCLAB (South SanFrancisco, Calif.). Both antibodies are tested to determine which oneproduces the most effective CAR in assays described below. As shownbelow, second or third (FIG. 6) generation CAR vectors are constructedconsisting of the following tandem genes: a kozak consensus sequence;the CD8 signal peptide; the anti-HLA-DR heavy chain variable region; a(Glycine4Serine)3 flexible polypeptide linker (SEQ ID NO: 51); therespective anti-HLA-DR light chain variable region; CD8 hinge andtransmembrane domains; and the CD28, 4-1BB, and CD3ζ intracellularco-stimulatory signaling domains. Hinge, transmembrane, and signalingdomain DNA sequences are ascertained from a patent by Carl June (seeU.S. Patent Application Publication No. 2013/0287748 A1). Anti-HLA-DRCAR genes are synthesized by Genewiz, Inc. (South Plainfield, N.J.)within a pUC57 vector backbone containing the bla gene, which confersampicillin resistance to the vector host.

Subcloning of CAR Genes into Lentiviral Plasmids

NovaBlue Singles™ chemically-competent E. coli cells are transformedwith anti-HLA-DR plasmid cDNA. Following growth of the transformed E.coli cells, the CAR plasmids are purified and digested with theappropriate restriction enzymes to be inserted into an HIV-1-basedlentiviral vector containing HIV-1 long terminal repeats (LTRs),packaging signal (Ψ), EF1α promoter, internal ribosome entry site(IRES), and woodchuck hepatitis virus post-transcriptional regulatoryelement (WPRE) via overnight T₄ DNA ligase reaction (New EnglandBiosciences; Ipswich, Mass.). NovaBlue Singles™ chemically-competent E.coli cells are then transformed with the resulting anti-HLA-DRcontaining lentiviral plasmid.

Production of Lentiviral Particles

Prior to transfection, HEK293T cells are seeded at 4.0×10⁶ cells/100 mmtissue-culture-treated plate in 10 mL complete-Tet-DMEM and incubatedovernight at 37° C. in a humidified 5% CO₂ incubator. Once 80-90%confluent, HEK293T cells are co-transfected with

CAR-gene lentiviral plasmids and lentiviral packaging plasmidscontaining genes necessary to form lentiviral envelope & capsidcomponents, in addition to a proprietary reaction buffer and polymer tofacilitate the formation of plasmid-containing nanoparticles that bindHEK293T cells. After incubating transfected-HEK293T cell cultures for 4hours at 37° C., the transfection medium is replaced with 10 mL freshcomplete Tet DMEM. HEK293T cells are then incubated for an additional 48hours, after which cell supernatants are harvested and tested forlentiviral particles via sandwich ELISA against p24, the main lentiviralcapsid protein. Lentivirus-containing supernatants are aliquoted andstored at −80° C. until use for transduction of target CD4⁺ and CD8⁺ Tcells.

Purification, Activation, and Enrichment of Human CD4⁺ and CD8⁺Peripheral Blood T-Cells

Peripheral blood mononuclear cells (PBMCs) are enriched by densitygradient centrifugation with Ficoll-Paque Plus (GE Healthcare; LittleChalfont, Buckinghamshire, UK) are recovered and washed bycentrifugation with PBS containing 0.5% bovine serum albumin (BSA) and 2mM EDTA. MACS CD4⁺ and CD8⁺ MicroBeads (Miltenyi Biotec; San Diego,Calif.) kits are used to isolate these human T-cell subsets usingmagnetically activated LS columns to positive select for CD4⁺ and CD8⁺T-cells. Magnetically-bound T-cells are then removed from the magneticMACS separator, flushed from the LS column, and washed in fresh completemedium. The purity of CD4⁺ and CD8⁺ T-cell populations are assessed byflow cytometry using Life Technologies Acoustic Attune® Cytometer, andare enriched by Fluorescence-Activated Cell Sorting performed at USC'sflow cytometry core facilities if needed. CD4⁺ and CD8⁺ T-cells aremaintained at a density of 1.0×10⁶ cells/mL in complete mediumsupplemented with 100 IU/mL IL-2 in a suitable cell culture vessel, towhich α-CD3/α-CD28 Human T-cell Dynabeads (Life Technologies; Carslbad,Calif.) are added to activate cultured T cells. T-cells are incubated at37° C. in a 5% CO₂ incubator for 2 days prior to transduction withCAR-lentiviral particles.

Lentiviral Transduction of CD4⁺ CD8⁺ T-Cells

Activated T-cells are collected and dead cells are removed byFicoll-Hypaque density gradient centrifugation or the use of MACS DeadCell Removal Kit (Miltenyi Biotec; San Diego, Calif.). In a 6-wellplate, activated T-cells are plated at a concentration of 1.0×10⁶cells/mL complete medium. To various wells, HLA-DR CAR-containinglentiviral particles are added to cell suspensions at varyingmultiplicity of infections (MOIs), such as 1, 5, 10, and 50. Polybrene,a cationic polymer that aids transduction by facilitating interactionbetween lentiviral particles and the target cell surface, are added at afinal concentration of 4 μg/mL. Plates are centrifuged at 800×g for 1 hrat 32° C. Following centrifugation, lentivirus-containing medium areaspirated and cell pellets are resuspended in fresh complete medium with100 IU/mL IL-2. Cells are placed in a 5% CO₂ humidified incubator at 37°C. overnight. Three days post-transduction, cells are pelleted andresuspended in fresh complete medium with IL-2 and 400 μg/mL Geneticin(G418 sulfate) (Life Technologies; Carlsbad, Calif.). HLA-DR CARmodified T-cells are assessed by flow cytometry and southern blotanalysis to demonstrate successful transduction procedures. Prior to invitro and in vivo assays, HLA-DR CAR T-cells are enriched by FACS andmixed 1:1 for the in vivo studies.

In Vitro Assessment of CAR Efficacy by Calcein-Release CytotoxicityAssays

HLA-DR antigen positive and negative human cell lines are collected,washed, and resuspended in complete medium at a concentration of 1.0×10⁶cells/mL. Calcein-acetoxymethyl (AM) are added to target cell samples at15 which are then incubated at 37° C. in a 5% CO₂ humidified incubatorfor 30 minutes. Dyed positive and negative target cells are washed twiceand resuspended in complete medium by centrifugation and added to a96-well plate at 1.0×10⁴ cells/well. HLA-DR CAR T-cells are added to theplate in complete medium at effector-to-target cell ratios of 50:1, 5:1,and 1:1. Dyed-target cells suspended in complete medium and completemedium with 2% triton X-100 serve as spontaneous and maximal releasecontrols, respectively. The plates are centrifuged at 365×g and 20° C.for 2 minutes before being placed back in the incubator 3 hours. Theplates are then centrifuged 10 minutes and cell supernatants arealiquoted to respective wells on a black polystyrene 96-well plate andassessed for fluorescence on a Bio-Tek® Synergy™ HT microplate reader atexcitation and emissions of 485/20 nm and 528/20 nm, respectively.

Quantification of Human Cytokines by Luminex Bioassay

Supernatants of HLA-DR CAR modified T-cells and HLA-DR positive andnegative tumor cell lines are measured for cytokine secretion as ameasure of CAR T-cell activation using standard procedures performedroutinely in the laboratory. Data are compared to medium alone and tocultures using non-activated human T-cells to identify backgroundactivity. The concentration of IL-2, IFN-g, IL-12, and other pertinentcytokines are measured over time during the incubation process.

In Vivo Assessment of CAR T-Cell Efficacy in Two Xenograft HLA-DRPositive Cancer Models

HLA-DR CAR T-cells are further evaluated in vivo using two differenthuman tumor cell line xenograft tumor models. For both, solid tumors areestablished subcutaneously in 6-8 week old female nude mice by injectionof 5×10⁶ HLA-DR positive or HLA-DR negative solid tumor cell lines. Whenthe tumors reach 0.5 cm in diameter, groups of mice (n=5) are treatedintravenously with 1 or 3×10⁷ human T-cells as negative controls orHLA-DR CAR T-cells constructed from the most active HLA-DR antibodiesbased upon the in vitro study results. Tumor volumes are then measuredby caliper 3×/week and volume growth curves are generated to demonstratethe effectiveness of experimental treatments over controls.

HLA-DR is found to be an outstanding target for CAR T-cell development.

Example 3—Lym-1 CAR Cells Construction of the CAR Lentiviral Constructs

The Lym-1 CAR vector contains a CD8 leader sequence followed by theextracellular antigen binding moiety or scFV, which binds specificallyto Lym-1 antigen. The scFV is connected via a CD8 hinge region to thecytoplasmic signaling domain, comprised of the CD8 transmembrane region,and the signaling domains from 4-1BB and CD3 (FIG. 7). The CAR sequenceincluding the signaling domains, were synthetically synthesized byGenewiz Gene Synthesis services (Piscataway, N.J.). The plasmids arepurified and digested with the appropriate restriction enzymes to beinserted into an HIV-1-based lentiviral vector (pLVX-IRES-ZsGreen,Clontech, Signal Hill, Calif.) containing HIV-1 5′ and 3′ long terminalrepeats (LTRs), packaging signal (Ψ), EF1α promoter, internal ribosomeentry site (IRES), woodchuck hepatitis virus post-transcriptionalregulatory element (WPRE) and simian virus 40 origin (SV40) viaovernight T4 DNA ligase reaction (New England Biosciences; Ipswich,Mass.), followed by deletion of the IRES-ZsGreen using restrictionenzyme digestion and ligation with T4 DNA ligase. NovaBlue Singles™chemically-competent E. coli cells are then transformed with theresulting CAR-containing lentiviral plasmid.

Production of Lentiviral Particles

Prior to transfection, HEK 293T cells are seeded at 4.0×106 cells in a150 cm2 tissue-culture-treated flask in 20 mL DMEM supplemented with 10%dialyzed FCS and incubated overnight at 37° C. in a humidified 5% CO2incubator. Once 80-90% confluent, HEK 293T cells are incubated in 20 mlDMEM supplemented with 1-% dialyzed FCS without penicillin/streptamycinfor two hours in at 37° C. in a humidified 5% CO2 incubator. HEK293Tcells are co-transfected with the CAR plasmid and lentiviral packagingplasmids containing genes necessary to form the lentiviral envelope &capsid components. A proprietary reaction buffer and polymer tofacilitate the formation of plasmid-containing nanoparticles that bindHEK 293T cells are also added. After incubating the transfected-HEK 293Tcell cultures for 24 hours at 37° C., the transfection medium isreplaced with 20 mL fresh complete DMEM. Lentivirus supernatants arecollected every 24 hours for three days and the supernatants arecentrifuged at 1,250 rpm for 5 mins at 4° C., followed by filtersterilization and centrifugation in an ultracentrifuge at 20,000 g for 2hrs at 4° C. The concentrated lentivirus is re-suspended in PBAcontaining 7% trehalose and 1% BSA. The lentivirus is then aliquoted andstored at −80° C. until use for transduction of target CD4+ and CD8+ Tcells. The cell supernatants harvested after 24 hours are tested forlentiviral particles via sandwich ELISA against p24, the main lentiviralcapsid protein. Transfection efficiency was estimated between 20%-50%,by staining with a biotin-labeled Protein L antibody (Genscript,Piscataway, N.J.), followed by incubation with a streptavidin conjugatedto PE, and detection by FACS analysis.

Purification, Activation, and Enrichment of Human CD4+ and CD8+Peripheral Blood T-Cells

Peripheral blood mononuclear cells (PBMCs) enriched by density gradientcentrifugation with Ficoll-Paque Plus (GE Healthcare; Little Chalfont,Buckinghamshire, UK) are recovered and washed by centrifugation with PBScontaining 0.5% bovine serum albumin (BSA) and 2 mM EDTA. T-cellenrichment kits (Stem Cell Technologies) are used to isolate these humanT-cell subsets magnetically using negative selection for CD4+ and CD8+T-cells. The purity of CD4+ and CD8+ T-cell populations is assessed byflow cytometry using Life Technologies Acoustic Attune® Cytometer, andare enriched by Fluorescence-Activated Cell Sorting. CD4+ and CD8+T-cells mixed 1:1 are maintained at a density of 1.0×106 cells/mL incomplete 50% Click's medium/50% RPMI-1640 medium supplemented with 100IU/mL IL-2 in a suitable cell culture vessel, to which α-CD3/α-CD28Human T-cell activator beads (Stem Cell Technologies) are added toactivate cultured T cells. T-cells are then incubated at 37° C. in a 5%CO2 incubator for 2 days prior to transduction with CAR lentiviralparticles.

Lentiviral Transduction of CD4+ CD8+ T-Cells

Activated T-cells are collected and dead cells are removed byFicoll-Hypaque density gradient centrifugation or the use of MACS DeadCell Removal Kit (Miltenyi Biotec; San Diego, Calif.). In a 6-wellplate, activated T-cells will be plated at a concentration of 1.0×106cells/mL in complete medium. Cells will be transduced with thelentiviral particles supplemented with Lentiblast, a transfection aid(Oz Biosciences, San Diego, Calif.) to the cells. Transduced cells wereincubated for 24 hours at 37° C. in a humidified 5% CO2 incubator. Thecells are spun down and the media changed, followed by addition of theT-cell activator beads (Stem Cell Technologies, San Diego, Calif.).

Detection of Lym-1 CAR Expression by Flow Cytometry

Seven days after Lentivirus transduction, primary T-cells are washed 3×using wash buffer (4% BSA in PBS). Cells are incubated withBiotein-Protein L (2 ug, Genscript, Piscataway, N.J.) at 4° C. for 45min. Cells are again washed 3× with wash buffer, followed by incubationwith 2 ul of Streptavidin-PE (BD Sciences, La Jolla, Calif.) at 4° C.for 45 min. Cells are washed 3× and analyzed using flow cytometry(Attune Cytometer, Applied Biosciences, Carlsbad, Calif.).

Cell Cytotoxicity Assays

Cytotoxicity of the Lym-1 CAR T-cells are determined using the lactatedehydrogenase (LDH) cytotoxicity kit (Thermo Scientific, Carlsbad,Calif.). Activated T-cells are collected and 1×106 cells are transducedwith the Lym-1 CAR lentiviral construct as described above. Cells areactivated used the T-cell activator beads (Stem Cell Technologies, SanDiego, Calif.) for two days prior to cytotoxicity assays. The optimalnumber of target cells is determined as per the manufacturer's protocol.For the assays, the appropriate target cells are plated in triplicate ina 96 well plate for 24 hours at 37° C. in a 5% CO2 incubator, followedby addition of activated CAR T-cells in ratios of 20:1, 10:1, 5:1 and1:1, and incubated for 24 hours at 37° C. in a 5% CO2 incubator. Cellsare lysed at 37° C. for 45 mins and spun down at 1,250 rpm for 5minutes. The supernatants are transferred to a fresh 96 well plate,followed by the addition of the reaction mixture for 30 minutes. Thereaction is stopped using the stop solution and the plate read at 450 nmwith an absorbance correction at 650 nm.

In Vivo Tumor Regression Assay

Foxn1 null mice are injected with immortalized B lymphoma cell line,Raji, which expresses the Lym-1 antigen. Two×106 Raji cells with 1×106human fibroblasts in 200 ul of phosphate buffered saline (PBS) areinjected into the left flank of pre-irradiated mice (400 rads) to reducethe number of circulating NK cells enabling the heterotransplants toimplant at a high frequency. T-cells are activated for 2 days with theαCD3/CD28 activator complex (Stem Cell Technologies, San Diego, Calif.).The activated T-cells are then transduced with Lym-1 CAR lentiviralparticles, followed by activation with the αCD3/CD28 activator complexfor an additional 2 days. The activated T-cells expressing the Lym-1 CAR(2.5×106) are injected intravenously via the lateral tail vein into themice on day 7 after tumor inoculation. Tumor sizes are assessed 3×/weekusing Vernier calipers and the tumor volumes calculated.

Detection of Lym-1 CAR Expression

Analysis of the Lym-1 CAR T-cells for expression of the Lym-1 CAR,showed 62.5% of the transduced T-cells positive for Lym-1 (FIG. 8 middlepanel). In contrast, only 1% of the un-transduced T-cells used as acontrol were positive for CAR expression (FIG. 8 left panel). CD19transduced T-cells were used as a positive control and showed 52%expression of the CD19 CAR (FIG. 8 right panel).

Cytotoxicity for Lym-1 CAR T-Cells

The cytolytic activity of the Lym-1 CAR T-cells was examined using Raji,a B-cell lymphoma cell line. Raji expresses the Lym-1 antigen(HLA-Dr10), as determined by FACS analysis. Lym-1 CAR T-cells were addedto the Raji cells in ratios of 20:1, 10:1, 5:1 and 1:1 of effector totarget cells. Lym-1 CAR T-cells showed increased lysis of the targetRaji cells at ratios of 5:1, 10:1 and 20:1 with a lysis rate of 22%. Incomparison, untransduced T-cells did not lyse Raji cells at any of theratios tested.

Example 4—Lym-2 CAR Cells Construction of the CAR Lentiviral Constructs

The Lym-2 CAR vector contains a CD8 leader sequence followed by theextracellular antigen binding moiety or scFV, which binds specificallyto the Lym-2 antigen (HLA-Dr). The scFV is connected via a CD8 hingeregion to the cytoplasmic signaling domain, comprised of the CD8transmembrane region, and the signaling domains from 4-1BB and CD3. TheCAR sequence including the signaling domains, were syntheticallysynthesized by Genewiz Gene Synthesis services (Piscataway, N.J.). Theplasmids are purified and digested with the appropriate restrictionenzymes to be inserted into an HIV-1-based lentiviral vector(pLVX-IRES-ZsGreen, Clontech, Signal Hill, Calif.) containing HIV-1 5′and 3′ long terminal repeats (LTRs), packaging signal (Ψ), EF1αpromoter, internal ribosome entry site (IRES), woodchuck hepatitis viruspost-transcriptional regulatory element (WPRE) and simian virus 40origin (SV40) via overnight T₄ DNA ligase reaction (New EnglandBiosciences; Ipswich, Mass.), followed by deletion of the IRES-ZsGreenusing restriction enzyme digestion and ligation with T₄ DNA ligase.NovaBlue Singles™ chemically-competent E. coli cells are thentransformed with the resulting CAR-containing lentiviral plasmid.

Production of Lentiviral Particles

Prior to transfection, HEK 293T cells are seeded at 4.0×10⁶ cells in a150 cm² tissue-culture-treated flask in 20 mL DMEM supplemented with 10%dialyzed FCS and incubated overnight at 37° C. in a humidified 5% CO₂incubator. Once 80-90% confluent, HEK 293T cells are incubated in 20 mlDMEM supplemented with 1-% dialyzed FCS without penicillin/streptamycinfor two hours in a 37° C. humidified 5% CO₂ incubator. HEK293T cells areco-transfected with the CAR plasmid and lentiviral packaging plasmidscontaining genes necessary to form the lentiviral envelope & capsidcomponents. A proprietary reaction buffer and polymer to facilitate theformation of plasmid-containing nanoparticles that bind HEK 293T cellsare also added. After incubating the transfected-HEK 293T cell culturesfor 24 hours at 37° C., the transfection medium is replaced with 20 mLfresh complete DMEM. Lentivirus supernatants are collected every 24hours for 3 days and the supernatants are centrifuged at 1,250 rpm for 5mins at 4° C., followed by filter sterilization and centrifugation in anultracentrifuge at 20,000 g for 2 hrs at 4° C. The concentratedlentivirus is re-suspended in PBA containing 7% trehalose and 1% BSA.The lentivirus is aliquoted and stored at −80° C. until use fortransduction of target CD4⁺ and CD8⁺ T cells. The cell supernatantsharvested after 24 hours are tested for lentiviral particles via asandwich ELISA against p24, the main lentiviral capsid protein.Transfection efficiency was estimated between 20%-50%, by staining witha biotin-labeled Protein L antibody (Genscript, Piscataway, N.J.),followed by incubation with a streptavidin conjugated to PE, anddetection by FACS analysis.

Purification, Activation, and Enrichment of Human CD4⁺ and CD8⁺Peripheral Blood T-Cells

Peripheral blood mononuclear cells (PBMCs) enriched by density gradientcentrifugation with Ficoll-Paque Plus (GE Healthcare; Little Chalfont,Buckinghamshire, UK) are recovered and washed by centrifugation with PBScontaining 0.5% bovine serum albumin (BSA) and 2 mM EDTA. T-cellenrichment kits (Stem Cell Technologies) are used to isolate these humanT-cell subsets magnetically using negative selection for CD4⁺ and CD8⁺T-cells. The purity of CD4⁺ and CD8⁺ T-cell populations is assessed byflow cytometry using Life Technologies Acoustic Attune® Cytometer, andwill be enriched by Fluorescence-Activated Cell Sorting. CD4⁺ and CD8⁺T-cells mixed 1:1 are maintained at a density of 1.0×10⁶ cells/mL incomplete 50% Click's medium/50% RPMI-1640 medium supplemented with 100IU/mL IL-2 in a suitable cell culture vessel, to which α-CD3/α-CD28Human T-cell activator beads (Stem Cell Technologies) are added toactivate cultured T cells. T-cells are then incubated at 37° C. in a 5%CO₂ humidified incubator for 2 days prior to transduction with CARlentiviral particles.

Lentiviral Transduction of CD4⁺ CD8⁺ T-Cells

Activated T-cells are collected and dead cells removed by Ficoll-Hypaquedensity gradient centrifugation or the use of MACS Dead Cell Removal Kit(Miltenyi Biotec; San Diego, Calif.). In a 6-well plate, activatedT-cells are plated at a concentration of 1.0×10⁶ cells/mL in completemedium. Cells are transduced with the lentiviral particles supplementedwith Lentiblast, a transfection aid (Oz Biosciences, San Diego, Calif.)to the cells. Transduced cells are incubated for 24 hours at 37° C. in a37° C. humidified 5% CO₂ incubator. The cells are spun down and themedia changed, followed by addition of the T-cell activator beads (StemCell Technologies, San Diego, Calif.).

Cell Cytotoxicity Assays

Cytotoxicity of the Lym-2 CAR T-cells are determined using the lactatedehydrogenase (LDH) cytotoxicity kit (Thermo Scientific, Carlsbad,Calif.). Activated T-cells are collected and 1×10⁶ cells are transducedwith the Lym-2 CAR lentiviral construct as described above. Cells areactivated used the T-cell activator beads (Stem Cell Technologies, SanDiego, Calif.) for two days prior to cytotoxicity assays. The optimalnumber of target cells will be determined as per the manufacturer'sprotocol. For the assays, the appropriate target cells will be plated intriplicate in a 96 well plate for 24 hours at 37° C. in a 37° C.humidified 5% CO₂ incubator, followed by addition of activated CART-cells in ratios of 20:1, 10:1, 5:1 and 1:1, and incubated for 24 asabove. Cells will be lysed at 37° C. for 45 mins and centrifuged at1,250 rpm for 5 minutes. The supernatants are transferred to a fresh 96well plate, followed by the addition of the reaction mixture for 30minutes. The reaction is stopped using the stop solution and the plateread at 450 nm with an absorbance correction at 650 nm.

In Vivo Tumor Regression Assay

Foxn1 null mice are injected with immortalized B lymphoma cell line,Raji, which expresses the Lym-2 antigen. Two×10⁶ Raji cells with 1×10⁶human fibroblasts in 200 ul of phosphate buffered saline (PBS) areinjected into the left flank of the pre-irradiated (400 rads) BALB/cmice in insure a high take rate of tumor. T-cells are activated for 2days with the αCD3/CD28 activator complex (Stem Cell Technologies, SanDiego, Calif.). The activated T-cells are then transduced with Lym-2 CARlentiviral particles, followed by activation with the αCD3/CD28activator complex for an additional 2 days. The activated T-cellsexpressing the Lym-2 CAR (2.5×10⁶) are injected intravenously into themice on day 7 after tumor inoculation. Tumor sizes are assessed 3×/weekusing Vernier calipers and the tumor volumes calculated.

Detection of Lym-2 CAR Expression

Analysis of the Lym-2 CAR T-cells for expression of the Lym-1 CAR,showed 28% of the transduced T-cells positive for Lym-2 (FIG. 11 middlepanel). In contrast, only 1% of the un-transduced T-cells used as acontrol were positive for CAR expression (FIG. 11 left panel). CD19transduced T-cells were used as a positive control and showed 52%expression of the CD19 CAR (FIG. 11 right panel).

Cytotoxicity for Lym-2 CAR T-Cells

The cytolytic activity of the Lym-2 CAR T-cells was determined usingRaji, a B-cell lymphoma cell line. Raji expresses the Lym-2 antigen, asdetermined by FACS analysis. Lym-2 CAR T-cells were added to the Rajicells in ratios of 20:1, 10:1, 5:1 and 1:1 of effector to target cells.Lym-2 CAR T-cells show increased lysis of the target Raji cells atratios of 5:1 and 10:1 with a lysis rate of 22%. In comparison,untransduced T-cells did not lyse Raji cells at any of the ratiostested.

Example 5—NK Cell Transduction NK-92MI Transduction

NK-92Mi cell line was purchased from ATCC (CRL-2408) and maintained inRPMI-1640 with 10% FBS. Before transduction, non-tissue treated 24-wellswere incubated with 10 μg RetroNectin (Clontech T100A) in 300 μLPhosphate Buffered Saline (PBS) at room temperature for 2 hours. Onemillion NK-92Mi cells and lentivirus (MOI=5) were mixed and added to theRetroNectin coated plates. The plates were then centrifuged at 28° C.800 g for 90 min. After centrifugation, the cells were maintained in acell culture incubator overnight. After incubation, the cells werewashed with PBS three times the following morning and the transducedNK-92Mi cells were then transferred to 24 well G-Rex (Wilson Wolf)plates for expansion. Seven days after Lentivirus transduction, thecells were washed 3× in wash buffer (4% BSA in PBS), stained withBiotein-Protein L (1 ug/1 million cells. Genscript) at 4° C. for 45 min,and washed 3× with wash buffer before adding 2 ul Streptavidin-APC (BDscience) at 4° C. for 45 min. After a final 3 washes in wash buffer, thecells were analyzed by FACs (Attune) (FIG. 15).

EQUIVALENTS

Unless otherwise defined, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this technology belongs.

The present technology illustratively described herein may suitably bepracticed in the absence of any element or elements, limitation orlimitations, not specifically disclosed herein. Thus, for example, theterms “comprising,” “including,” “containing,” etc. shall be readexpansively and without limitation. Additionally, the terms andexpressions employed herein have been used as terms of description andnot of limitation, and there is no intention in the use of such termsand expressions of excluding any equivalents of the features shown anddescribed or portions thereof, but it is recognized that variousmodifications are possible within the scope of the present technologyclaimed.

Thus, it should be understood that the materials, methods, and examplesprovided here are representative of preferred aspects, are exemplary,and are not intended as limitations on the scope of the presenttechnology.

The present technology has been described broadly and genericallyherein. Each of the narrower species and sub-generic groupings fallingwithin the generic disclosure also form part of the present technology.This includes the generic description of the present technology with aproviso or negative limitation removing any subject matter from thegenus, regardless of whether or not the excised material is specificallyrecited herein.

In addition, where features or aspects of the present technology aredescribed in terms of Markush groups, those skilled in the art willrecognize that the present technology is also thereby described in termsof any individual member or subgroup of members of the Markush group.

All publications, patent applications, patents, and other referencesmentioned herein are expressly incorporated by reference in theirentirety, to the same extent as if each were incorporated by referenceindividually. In case of conflict, the present specification, includingdefinitions, will control.

Other aspects are set forth within the following claims.

1.-51. (canceled)
 52. An isolated anti-Lym-2 antibody or an antigenbinding fragment thereof comprising a heavy chain variable regioncomprising complementarity-determining regions (CDRs) comprising SEQ IDNOs: 2, 4, and 6; and a light chain variable region comprising CDRscomprising SEQ ID NOs: 12, 14, and
 16. 53. The isolated anti-Lym-2antibody or the antigen binding fragment thereof of claim 52, whereinthe heavy chain variable region comprises a polypeptide comprising atleast 90% sequence identity to SEQ ID NO: 10 and comprising the CDRscomprising of SEQ ID NOs: 2, 4, 6, 12, 14 and
 16. 54. The isolatedanti-Lym-2 antibody or the antigen binding fragment thereof of claim 52,wherein the heavy chain variable region comprises SEQ ID NO:
 10. 55. Theisolated anti-Lym-2 antibody or the antigen binding fragment thereof ofclaim 52, wherein the light chain variable region comprises apolypeptide comprising at least 90% sequence identity to SEQ ID NO: 20and comprising the CDRs comprising of SEQ ID NOs: 2, 4, 6, 12, 14 and16.
 56. The isolated anti-Lym-2 antibody or the antigen binding fragmentthereof of claim 52, wherein the light chain variable region comprisesSEQ ID NO:
 20. 57. The isolated anti-Lym-2 antibody or the antigenbinding fragment thereof of claim 52, wherein the fragment of theisolated anti-Lym-2 antibody is a scFv.
 58. The isolated anti-Lym-2antibody of claim 52, wherein the isolated anti-Lym-2 antibody is amonoclonal antibody.
 59. An isolated nucleic acid sequence encoding theisolated anti-Lym-2 antibody or the antigen binding fragment thereof ofclaim 52 or its complement or an equivalent of each thereof.
 60. Avector comprising the isolated nucleic acid sequence of claim
 59. 61. Anisolated cell comprising the isolated anti-Lym-2 antibody or the antigenbinding fragment thereof of claim
 52. 62. A complex comprising theisolated anti-Lym-2 antibody or the antigen binding fragment thereof ofclaim 52 bound to a cell expressing HLA-DR.
 63. A method of inhibitingthe growth of a tumor or treating a cancer that overexpresses HLA-DR ascompared to a normal, non-cancerous counterpart cell in a subject inneed thereof, comprising administering to the subject an effectiveamount of the isolated anti-Lym-2 antibody or the antigen bindingfragment thereof of claim
 52. 64. The method of claim 63, furthercomprising administering to the subject an anti-tumor therapy other thanan HLA-DR CAR therapy.
 65. The method of claim 63, wherein the tumor iscancerous.
 66. The method of claim 63, wherein the cancer is a B-celllymphoma or a leukemia.
 67. The method of claim 63, wherein the subjectis a mammal.